|Part of a series on the|
COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main branches detect either the presence of the virus or of antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests (serology immunoassays) instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.
Individual jurisdictions have adopted varied testing protocols, including whom to test, how often to test, analysis protocols, sample collection and the uses of test results. This variation has likely significantly impacted reported statistics, including case and test numbers, case fatality rates and case demographics. Because SARS-CoV-2 transmission occurs days after exposure (and before onset of symptoms) there is an urgent need for frequent surveillance and rapid availability of results.
Test analysis is often performed in automated, high-throughput, medical laboratories by medical laboratory scientists. Alternatively, point-of-care testing can be done in physician's offices and parking lots, workplaces, institutional settings or transit hubs.
Positive viral tests indicate a current infection, while positive antibody tests indicate a prior infection. Other techniques include a CT scan, checking for elevated body temperature, checking for low blood oxygen level, and the deployment of detection dogs at airports.
Detection of the virus
Detection of the virus is usually done either by looking for the virus' inner DNA, or pieces of protein on the outside of the virus. Tests that look for the viral antigens (parts of the virus) are called antigen tests.
There are multiple types of tests that look for the virus by detecting the presence of the virus's DNA. These are called molecular tests, after molecular biology. As of 2021[update], the most common form of molecular test is the reverse transcription polymerase chain reaction (RT-PCR) test. Other methods used in molecular tests include CRISPR, isothermal nucleic acid amplification, digital polymerase chain reaction, microarray analysis, and next-generation sequencing.
Reverse transcription polymerase chain reaction test
Polymerase chain reaction (PCR) is a process that amplifies (replicates) a small, well-defined segment of DNA many hundreds of thousands of times, creating enough of it for analysis. Test samples are treated with certain chemicals that allow DNA to be extracted. Reverse transcription converts RNA into DNA.
Reverse transcription polymerase chain reaction (RT-PCR) first uses reverse transcription to obtain DNA, followed by PCR to amplify that DNA, creating enough to be analyzed. RT-PCR can thereby detect SARS-CoV-2, which contains only RNA. The RT-PCR process generally requires a few hours. These tests are also referred to as molecular or genetic assays.
The combined technique has been described as real-time RT-PCR or quantitative RT-PCR and is sometimes abbreviated qRT-PCR, rRT-PCR or RT-qPCR, although sometimes RT-PCR or PCR are used. The Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines propose the term RT-qPCR, but not all authors adhere to this.
Average sensitivity for rapid molecular tests were 95.2% (ranging from 68% to 100%) and average specificity was 98.9% (ranging from 92% to 100%) between test results of different company brands and sampling methods.[needs update] The term sensitivity refers to the capacity of a test to identify all infected people, while specificity is the ability of a test to detect a particular virus.
Samples can be obtained by various methods, including a nasopharyngeal swab, sputum (coughed up material), throat swabs, deep airway material collected via suction catheter or saliva. Drosten et al. remarked that for 2003 SARS, "from a diagnostic point of view, it is important to note that nasal and throat swabs seem less suitable for diagnosis, since these materials contain considerably less viral RNA than sputum, and the virus may escape detection if only these materials are tested."
The likelihood of detecting the virus depends on collection method and how much time has passed since infection. According to Drosten tests performed with throat swabs are reliable only in the first week. Thereafter the virus may abandon the throat and multiply in the lungs. In the second week, sputum or deep airways collection is preferred.
Collecting saliva may be as effective as nasal and throat swabs, although this is not certain. Sampling saliva may reduce the risk for health care professionals by eliminating close physical interaction. It is also more comfortable for the patient. Quarantined people can collect their own samples. A saliva test's diagnostic value depends on sample site (deep throat, oral cavity, or salivary glands). Some studies have found that saliva yielded greater sensitivity and consistency when compared with swab samples.
On 4 January 2021, the US FDA issued an alert about the risk of false results, particularly false negative results, with the Curative SARS-Cov-2 Assay real-time RT-PCR test.
Demonstration of a nasopharyngeal swab for COVID-19 testing
Demonstration of a throat swab for COVID-19 testing
Other molecular tests
Isothermal nucleic acid amplification tests also amplify the virus's genome. They are faster than PCR because they don't involve repeated heating and cooling cycles. These tests typically detect DNA using fluorescent tags, which are read out with specialized machines.
CRISPR gene editing technology was modified to perform the detection: if the CRISPR enzyme attaches to the sequence, it colors a paper strip. The researchers expect the resulting test to be cheap and easy to use in point-of-care settings. The test amplifies RNA directly, without the RNA-to-DNA conversion step of RT-PCR.
An antigen is the part of a pathogen that elicits an immune response. Antigen tests look for antigen proteins from the viral surface. In the case of a coronavirus, these are usually proteins from the surface spikes. SARS-CoV-2 antigens can be detected before onset of COVID-19 symptoms (as soon as SARS-CoV-2 virus particles) with more rapid test results, but with less sensitivity than PCR tests for the virus.
Antigen tests may be one way to scale up testing to much greater levels. Isothermal nucleic acid amplification tests can process only one sample at a time per machine. RT-PCR tests are accurate but require too much time, energy and trained personnel to run the tests. "There will never be the ability on a [PCR] test to do 300 million tests a day or to test everybody before they go to work or to school," Deborah Birx, head of the White House Coronavirus Task Force, said on 17 April 2020. "But there might be with the antigen test."
Samples may be collected via nasopharyngeal swab, a swab of the anterior nares, or from saliva. The sample is then exposed to paper strips containing artificial antibodies designed to bind to coronavirus antigens. Antigens bind to the strips and give a visual readout. The process takes less than 30 minutes, can deliver results at point of care, and does not require expensive equipment or extensive training.
Swabs of respiratory viruses often lack enough antigen material to be detectable. This is especially true for asymptomatic patients who have little if any nasal discharge. Viral proteins are not amplified in an antigen test. According to the WHO the sensitivity of similar antigen tests for respiratory diseases like the flu ranges between 34% and 80%. "Based on this information, half or more of COVID-19 infected patients might be missed by such tests, depending on the group of patients tested," the WHO said. While some scientists doubt whether an antigen test can be useful against COVID-19, others have argued that antigen tests are highly sensitive when viral load is high and people are contagious, making them suitable for public health screening. Routine antigen tests can quickly identify when asymptomatic people are contagious, while follow-up PCR can be used if confirmatory diagnosis is needed.
The average specificity of antigen tests was found in a review by Dinnes et al. to be 99.5%, and the average sensitivity was 56.2%. There was very strong variation in the sensitivity results (ranging from 0% to 94%) between test results of different company brands.
Sudden loss of smell can be used to screen people on a daily basis for COVID-19. A study by the National Institutes of Health showed that those infected with SARS-CoV-2 could not smell a 25% mixture of ethanol and water. Because various conditions can lead to the loss of the sense of smell, a sniff test would not be definitive but indicate the need for a PCR test. Because the loss of the sense of smell shows up before other symptoms, there has been a call for widespread sniff testing. Health care bureaucracies have generally ignored sniff tests even though they are quick, easy and capable of being self-administered daily. This has led some medical journals to write editorials supporting the adoption of sniff testing.
Typical visible features on CT initially include bilateral multilobar ground-glass opacities with a peripheral or posterior distribution. COVID-19 can be identified with higher precision using CT than with RT-PCR.
Subpleural dominance, crazy paving, and consolidation may develop as the disease evolves. Chest CT scans and chest x-rays are not recommended for diagnosing COVID-19. Radiologic findings in COVID-19 lack specificity.
The body responds to a viral infection by producing antibodies that help neutralize the virus. Blood tests (also called serology tests or serology immunoassays) can detect the presence of such antibodies. Antibody tests can be used to assess what fraction of a population has once been infected, which can then be used to calculate the disease's mortality rate. They can also be used to determine how much antibody is contained in a unit of convalescent plasma, for COVID-19 treatment, or to verify if a given vaccine generates an adequate immune response.
SARS-CoV-2 antibodies' potency and protective period have not been established. Therefore, a positive antibody test may not imply immunity to a future infection. Further, whether mild or asymptomatic infections produce sufficient antibodies for a test to detect has not been established. Antibodies for some diseases persist in the bloodstream for many years, while others fade away.
The most notable antibodies are IgM and IgG. IgM antibodies are generally detectable several days after initial infection, although levels over the course of infection and beyond are not well characterized. IgG antibodies generally become detectable 10–14 days after infection and normally peak around 28 days after infection. This pattern of antibody development seen with other infections, often does not apply to SARS-CoV-2, however, with IgM sometimes occurring after IgG, together with IgG or not occurring at all. Generally, however, median IgM detection occurs 5 days after symptom onset, whereas IgG is detected a median 14 days after symptom onset. IgG levels significantly decline after two or three months.
Genetic tests verify infection earlier than antibody tests. Only 30% of those with a positive genetic test produced a positive antibody test on day 7 of their infection.
Rapid diagnostic test (RDT)
RDTs typically use a small, portable, positive/negative lateral flow assay that can be executed at point of care. RDTs may process blood samples, saliva samples, or nasal swab fluids. RDTs produce colored lines to indicate positive or negative results.
ELISAs can be qualitative or quantitative and generally require a lab. These tests usually use whole blood, plasma, or serum samples. A plate is coated with a viral protein, such as a SARS-CoV-2 spike protein. Samples are incubated with the protein, allowing any antibodies to bind to it. The antibody-protein complex can then be detected with another wash of antibodies that produce a color/fluorescent readout.
Neutralization assays assess whether sample antibodies prevent viral infection in test cells. These tests sample blood, plasma or serum. The test cultures cells that allow viral reproduction (e.g., VeroE6 cells). By varying antibody concentrations, researchers can visualize and quantify how many test antibodies block virus replication.
Chemiluminescent immunoassays are quantitative lab tests. They sample blood, plasma, or serum. Samples are mixed with a known viral protein, buffer reagents and specific, enzyme-labeled antibodies. The result is luminescent. A chemiluminescent microparticle immunoassay uses magnetic, protein-coated microparticles. Antibodies react to the viral protein, forming a complex. Secondary enzyme-labeled antibodies are added and bind to these complexes. The resulting chemical reaction produces light. The radiance is used to calculate the number of antibodies. This test can identify multiple types of antibodies, including IgG, IgM, and IgA.
Neutralizing vis-à-vis binding antibodies
Most if not all large scale COVID-19 antibody testing looks for binding antibodies only and does not measure the more important neutralizing antibodies (NAb). A NAb is an antibody that defends a cell from an infectious particle by neutralizing its biological effects. Neutralization renders the particle no longer infectious or pathogenic. A binding antibody binds to the pathogen but the pathogen remains infective; the purpose can be to flag the pathogen for destruction by the immune system. It may even enhance infectivity by interacting with receptors on macrophages. Since most COVID-19 antibody tests return a positive result if they find only binding antibodies, these tests cannot indicate that the subject has generated protective NAbs that protect against re-infection.
It is expected that binding antibodies imply the presence of NAbs and for many viral diseases total antibody responses correlate somewhat with NAb responses but this is not established for COVID-19. A study of 175 recovered patients in China who experienced mild symptoms reported that 10 individuals had no detectable NAbs at discharge, or thereafter. How these patients recovered without the help of NAbs and whether they were at risk of re-infection was not addressed. An additional source of uncertainty is that even if NAbs are present, viruses such as HIV can evade NAb responses.
Studies have indicated that NAbs to the original SARS virus (the predecessor to the current SARS-CoV-2) can remain active for two years and are gone after six years. Nevertheless, memory cells including Memory B cells and Memory T cells can last much longer and may have the ability to reduce reinfection severity.
A point of care test in Peru. A blood droplet is collected by a pipette.
Blood from pipette is then placed onto a COVID-19 rapid diagnostic test device.
Following recovery, many patients no longer have detectable viral RNA in upper respiratory specimens. Among those who do, RNA concentrations three days following recovery are generally below the range in which replication-competent virus has been reliably isolated.
No clear correlation has been described between length of illness and duration of post-recovery shedding of viral RNA in upper respiratory specimens.
Pooled testing can improve turnaround time, by combining a number of samples to be tested together. If the pool result is negative, all samples are negative. If the test result is positive, samples will need to be individually tested.
In January 2020, scientists from China published the first genetic sequences of SARS-CoV-2 via GISAID, a program that normally handled genetic sequence data. Researchers around the world used that data to build molecular tests for the virus. Antigen- and antibody-based tests were developed later.
Even once the first tests were created, the supply was limited. As a result, no countries had reliable data on the prevalence of the virus early in the pandemic. The WHO and other experts called for ramping up testing as the best way to slow the spread of the virus. Shortages of reagent and other testing supplies became a bottleneck for mass testing in the EU, the UK and the US. Early tests also encountered problems with reliability.
In drive-through testing, the person undergoing testing remains in a vehicle while a healthcare professional approaches the vehicle and obtains a sample, all while taking appropriate precautions such as wearing personal protective equipment (PPE). Drive-through centers helped South Korea accelerate its testing program.
In Hong Kong test subjects can stay home and receive a specimen tube. They spit into it, return it and later get the result.
In Israel, researchers at Technion and Rambam Hospital developed a method for testing samples from 64 patients simultaneously, by pooling the samples and only testing further if the combined sample was positive. Pool testing was then adopted in Israel, Germany, Ghana South Korea, Nebraska, China and the Indian states of Uttar Pradesh, West Bengal, Punjab, Chhattisgarh and Maharashtra.
Open source, multiplexed designs released by Origami Assays can test as many as 1122 patient samples using only 93 assays. These balanced designs can be run in small laboratories without robotic liquid handlers.
One study proposed a rapid immune response assay as a screening test, with a confirmatory nucleic acid test for diagnosis, followed by a rapid antibody test to determine course of action and assess population exposure/herd immunity.
Required testing levels are a function of disease spread. The more the cases, the more tests are needed to manage the outbreak. COVID-19 tends to grow exponentially at the beginning of an outbreak, meaning that the number of required tests initially also grows exponentially. If properly targeted testing grows more rapidly than cases, it can be contained.
WHO recommends increasing testing until fewer than 10% are positive in any given jurisdiction.
Economist Paul Romer reported that the US has the technical capacity to scale up to 20 million tests per day, which is his estimate of the scale needed to fully remobilize the economy. The Edmond J. Safra Center for Ethics estimated on 4 April that this capacity could be available by late July. Romer pointed to single-molecule real-time sequencing equipment from Pacific Biosciences and to the Ion Torrent Next-Generation Sequencing equipment from ThermoFisher Scientific. According to Romer, "Recent research papers suggest that any one of these has the potential to scale up to millions of tests per day." This plan requires removing regulatory hurdles. Romer estimated that $100 billion would cover the costs.
Romer also claimed that high test accuracy is not required if tests are administered frequently enough. He ran model simulations in which 7% of the population is tested every day using a test with a 20% false negative rate and a 1% false positive rate. The average person would be tested roughly every two weeks. Those who tested positive would go into quarantine. Romer's simulation indicated that the fraction of the population that is infected at any given time (known as the attack rate) peaks reaches roughly 8% in about thirty days before gradually declining, in most runs reaching zero at 500 days, with cumulative prevalence remaining below 20%.
Countries around the world developed tests independently and in partnership with others.
Nucleic acid tests
Tests developed in China, France, Germany, Hong Kong, Japan, the United Kingdom, and the US targeted different parts of the viral genome. WHO adopted the German system for manufacturing kits sent to low-income countries without the resources to develop their own.
Abbott Laboratories' ID Now nucleic acid test uses isothermal amplification technology. The assay amplifies a unique region of the virus's RdRp gene; the resulting copies are then detected with "fluorescently-labeled molecular beacons". The test kit uses the company's "toaster-size" ID Now device, which is widely deployed in the US. The device can be used in laboratories or in point of care settings, and provides results in 13 minutes or less.
Primerdesign offers its Genesig Real-Time PCR Coronavirus (COVID‑19). Cobas SARS-CoV-2 Qualitative assay runs on the Cobas® 6800/8800 Systems by Roche Molecular Systems. They are offered by the United Nations and other procurement agencies.
Quidel's "Sofia 2 SARS Antigen FIA" is a lateral flow test that uses monoclonal antibodies to detect the virus's nucleocapsid (N) protein. The result is read out by the company's Sofia 2 device using immunofluorescence. The test is simpler and cheaper but less accurate than nucleic acid tests. It can be deployed in laboratories or at point of care and gives results in 15 minutes. A false negative result occurs if the sample's antigen level is positive but below the test's detection limit, requiring confirmation with a nucleic acid test.
Serology (antibody) tests
Antibodies are usually detectable 14 days after the onset of the infection. Multiple jurisdictions survey their populations using these tests. The test requires a blood draw.
A summary review in BMJ has noted that while some "serological tests … might be cheaper and easier to implement at the point of care [than RT-PCR]", and such testing can identify previously infected individuals, "caution is warranted … using serological tests for … epidemiological surveillance". The review called for higher quality studies assessing accuracy with reference to a standard of "RT-PCR performed on at least two consecutive specimens, and, when feasible, includ[ing] viral cultures." CEBM researchers have called for in-hospital 'case definition' to record "CT lung findings and associated blood tests" and for the WHO to produce a "protocol to standardise the use and interpretation of PCR" with continuous re-calibration.
The breath test by a Coronavirus breathalyzer is a pre-screening test for people who have no or mild symptoms of COVID-19.
|Samples source||Positive rate|
|Bronchoalveolar lavage fluid specimens||93% (14/15)|
|Nasal swabs||63% (5/8)|
|Fibrobronchoscope brush biopsy||46% (6/13)|
|Pharyngeal swabs||32% (126/398)|
Accuracy is measured in terms of specificity and selectivity. Test errors can be false positives (the test is positive, but the virus is not present) or false negatives, (the test is negative, but the virus is present).
Sensitivity and specificity
Sensitivity indicates whether the test accurately identifies whether the virus is present. Each test requires a minimum level of viral load in order to produce a positive result. A 90% sensitive test will correctly identify 90% of infections, missing the other 10% (a false negative). Even relatively high sensitivity rates can produce high rates of false negatives in populations with low incidence rates.
Specificity indicates how well-targeted the test is to the virus in question. Highly specific tests pick up only the virus in question. Non-selective tests pick up other viruses as well. A 90% specific test will correctly identify 90% of those who are uninfected, leaving 10% with a false positive result.
Low-specificity tests have a low positive predictive value (PPV) when prevalence is low. For example, suppose incidence is 5%. Testing 100 people at random using a test that has a specificity of 95% would yield on average 5 people who are actually negative who would incorrectly test positive. Since 5% of the subjects actually are positive, another five would also test positive correctly, totaling 10 positive results. Thus, the PPV is 50%, an outcome no different from a coin toss. In this situation retesting those with a positive result increases the PPV to 94.5%, meaning that only 4.5% of the second tests would return the incorrect result, on average less than 1 incorrect result.
Causes of test error
The time course of infection affects the accuracy of some tests. Samples may be collected before the virus has had a chance to establish itself or after the body has begun to eliminate it. A May 2020 review of PCR-RT testing found that the median probability of a false-negative result decreased from 100% on day 1, to 67% on day 4. On the day of symptom onset, the probability was 38%, which decreased to 20% 3 days later.[needs update]
Sensitivity is also a function of the number of PCR cycles, as well as time and temperature between sample collection and analysis. A cycle threshold of 20 cycles would be adequate to detect SARS-Cov-2 in a highly infective person. Cycle thresholds above 34 are increasingly likely to give false positives outside of high biosafety level facilities.
High sensitivity kits are recommended to assess people without symptoms, while lower sensitivity tests are adequate when diagnosing symptomatic patients.
The University of Oxford's Centre for Evidence-Based Medicine (CEBM) has pointed to mounting evidence that "a good proportion of 'new' mild cases and people re-testing positives via RT-PCR after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with", and have called for "an international effort to standardize and periodically calibrate testing". On 7 September, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results".
On 4 January 2021, the US FDA issued an alert about the risk of false results, particularly false negative results, with the Curative SARS-Cov-2 Assay real-time RT-PCR test.
Isothermal nucleic amplification test
One study reported that the ID Now COVID-19 test showed sensitivity of 85.2%. Abbott responded that the issue could have been caused by analysis delays. Another study rejected the test in their clinical setting because of this low sensitivity.
The WHO recommends countries that do not have testing capacity and national laboratories with limited experience on COVID‑19 send their first five positives and the first ten negative COVID‑19 samples to one of the 16 WHO reference laboratories for confirmatory testing. Out of the sixteen reference laboratories, seven are in Asia, five in Europe, two in Africa, one in North America and one in Australia.
Iceland managed the pandemic with aggressive contact tracing, inbound travel restrictions, testing, and quarantining, but with less aggressive lock-downs.
Researchers tested the entire population of Vò, the site of Italy's first COVID‑19 death. They tested about 3,400 people twice, at an interval of ten days. About half the people testing positive had no symptoms. All discovered cases were quarantined. Along with restricting travel to the commune, new infections were completely eliminated.
Unlike other Asian countries, Japan did not experience a pandemic of SARS or MERS, so the country's PCR testing system was not well developed. Japan preferentially tested patients with severe illness and their close contacts at the beginning. Japan's Novel Coronavirus Expert Meeting chose cluster measures to identify infections clusters. The Expert Meeting analyzed the outbreak from Wuhan and identified conditions leading to clusters (closed spaces, crowded spaces and close-contact), and asked people to avoid them.
In January, contact tracers took action shortly after the first infection was found. Only administrative tests were carried out at first, until insurance began covering PCR tests on 6 March. Private companies began to test, and the test system gradually expanded.
On 3 April, those with positive tests were legally permitted to recuperate at home or in a hotel if they had asymptomatic or mild illness, ending the hospital bed shortage. The first wave (from China) was contained, but a second wave (caused by returnees from Europe and the US) in mid-March led to spreading infection in April. On 7 April, Japan declared a state of emergency, (less strict than a lockdown, because it did not block cities or restrict outings). On 13 May, antigen test kits became covered by insurance, and were combined with a PCR test for diagnosis.
Japan's PCR test count per capita remained far smaller than in some other countries even though its positive test rate was lower. Excess mortality was observed in March.[failed verification][failed verification] The Expert Meeting stated, "The Japanese health care system originally carries out pneumonia surveillance, allowing it to detect most of the severely ill patients who develop pneumonia. There are a large number of CT scanners in Japan and they have spread to small hospitals all over the country, so pneumonia patients are rarely missed. In that sense, it meets the same standards as other countries that mainly carry out PCR tests." The group recommended using CT scans data and doctor's findings for diagnosis. On the Diamond Princess cruise ship, many people who initially tested negative later tested positive. Half of coronavirus-positives there who remained mild or asymptomatic had pneumonia findings on CT scans and their CT image showed a frosted glass shadow that is characteristic of infection.
As of 18 July, Japan's daily PCR testing capacity was about 32,000, more than three times the 10,000 cases as of April. When the antigen test is added to it, the number is about 58,000. The number of tests per 1,000 people in the United States is about 27 times that of Japan, the UK is 20 times, Italy is 8 times, and South Korea is twice (as of 26 July).
The number of those infected with coronavirus and inpatients has increased in July, but the number of serious cases has not increased. This is thought to be due to the proper testing of those infected in July compared to those in April. In April, the number of tests could not catch up with the increase in the number of infected people, and the test standards were strict, so the test positive rate exceeded 30% at the peak. It means that there were quite a few cases where the those infected was not PCR tested. It is thought that the severe case was preferentially tested though there were a lot of mild cases and asymptomatic carriers mainly in the young during the first wave. In other words, it became possible to grasp the actual situation of infection much better than before by strengthening the testing system. At the end of July, accommodation facilities for mild and asymptomatic carriers became full, and the authorities requested hospitals to prepare beds for the mild. However, it became difficult to treat patients with other illnesses and to maintain the ICU system including the staff due to the occupation of hospital beds by patients with mild symptoms.
On 27 April 2020, Russia tested 3 million people and had 183,000 positive results. On 28 April Anna Popova, head of Federal Service for Surveillance in Healthcare (Roszdravnadzor) stated that 506 laboratories were testing; that 45% of those who tested positive had no symptoms; that 5% of patients had a severe form; and 40% of infections were from family members. Illness improved from six days to one day after symptoms appeared. Antibody testing was carried out on 3,200 Moscow doctors, finding 20% immunity.
In late October 2020 Slovakia tested 3.62 million people in a weekend, from a population of 5.4m, representing 67% of the total (or 82% of the adult population), 38,359 tested positive, representing 1.06% of those tested. The government considered the mass test would significantly assist in controlling the virus and avoid a lockdown and may repeat the exercise at a later date.
South Korea's broad testing approach helped reduce spread. Testing capacity, largely in private sector labs, was built up over several years by the South Korean government in the early 2000s.
The government exploited the resident registration number (RRN) system. Authorities mobilized young men who were eligible for military service as social service agents, security and public health doctors. Public health doctors were mainly dispatched to public health centers and life treatment centers where mildly ill patients were accommodated. They performed PCR tests and managed mild patients. Social service agents worked in pharmacies to fill staff shortages. Korea's 10k PCR tests per million residents was the world's highest as of 13 April rising to 20k by mid-June. Twenty-seven Korean companies exported test kits worth $48.6 million in March, and were asked to provide test kits or humanitarian assistance by more than 120 countries. Korean authorities set up a treatment center to isolate and manage patients with asymptomatic and minor illnesses in one facility in order to vacate hospital beds for the more severely ill.
Centers were sited mainly at national facilities and corporate training centers. The failure of Korea's MERS quarantine in May 2015 left Korea more prepared for COVID-19 than countries that did not face that pandemic. Then President Park Geun-hye allowed Korean CDC-approved private sector testing for infectious diseases in 2016. Korea already had a system for isolating, testing and treating infectious disease patients separately from others. Patients with respiratory illness but no epidemiological relevance were treated at the National Hospital, and those with epidemiological relevance were treated at selected clinics.
Korea established a large scale drive-through/walk-through" test testing program. However, the most common method was "mobile examination". In Daegu City, 54% of samples were collected by 23 March in home or hospital. Collecting samples door-to-door of avoided the risk of travel by possibly infected patients, but required additional staff. Korea solved the problem by drafting more than 2,700 public insurance doctors.
The government disclosed personal information to the public via KCDC without patient consent. The authorities used digital surveillance to trace possible spread.
United Arab Emirates
In January 2021, the COVID-19 testing results of the UAE came under scrutiny, as Denmark suspended the Emirati flights for five days. The European nation said that it barred the flights from the UAE due to growing suspicion of irregularities in the testing process being followed in the Gulf nation. Denmark's Minister of Transport, Benny Engelbrecht said that they were taking time to ensure that the negative tests of travelers from the Emirates were a real screening carried out appropriately.
New York State
New York State's control measures consisted of PCR tests, stay-at-home measures and strengthening the healthcare system. On 29 February before its first case, the state allowed testing at the Wordsworth Center. They managed to convince the CDC to approve tests at state laboratories and the FDA to approve a test kit. As of 13 March the state was conducting more than 1,000 daily tests, growing to 10,000/day on 19 March. In April, the number exceeded 20,000. Many people queued at hospitals to get tested. On 21 March New York City health officials directed medical providers to test only those entering the hospital, for lack of PPE.
USS Theodore Roosevelt
Following an outbreak, 94% of the 4,800 aircraft carrier crew were tested. Roughly 60 percent of the 600-plus sailors who tested positive were asymptomatic. Five infected sailors who completed quarantine subsequently developed flu-like symptoms and again tested positive.
A shortage of trained medical laboratory scientists, assay reagents, analyzers, transport medium, and PPE coupled with high demand had limited initially limited the availability of testing and led to significantly increased turnaround times.
Testing statistics by country
Testing strategies vary by country and over time, with some countries testing very widely, while others have at times focused narrowly on only testing the seriously ill. The country that tests only people showing symptoms will have a higher figure for "Confirmed / tested" than the country that also tests others. If two countries are alike in every respect, including which people they test, the one that tests more people will have a higher "Confirmed / population". Studies have also found that countries that test more, relative to the number of deaths, have lower estimated case fatality rates and younger age distributions of cases.
|Country or region||Date[a]||Tested||Units[b]||Confirmed
|Afghanistan||17 Dec 2020||154,767||samples||49,621||32.1||0.40||0.13|||
|Albania||18 Feb 2021||428,654||samples||96,838||22.6||15.0||3.4|||
|Algeria||2 Nov 2020||230,553||samples||58,574||25.4||0.53||0.13|||
|Andorra||12 Apr 2021||175,789||samples||12,581||7.2||227||16.2|||
|Angola||12 Mar 2021||399,228||samples||20,981||5.3||1.3||0.067|||
|Antigua and Barbuda||6 Mar 2021||15,268||samples||832||5.4||15.9||0.86|||
|Argentina||16 Apr 2021||10,024,309||samples||2,658,628||26.5||22.1||5.9|||
|Armenia||17 Apr 2021||931,583||samples||207,973||22.3||31.6||7.0|||
|Australia||16 Apr 2021||16,303,749||samples||29,484||0.18||65.0||0.12|||
|Austria||16 Apr 2021||28,012,081||samples||585,510||2.1||315||6.6|||
|Azerbaijan||17 Apr 2021||3,096,740||samples||298,522||9.6||31.3||3.0|||
|Bahamas||15 Apr 2021||81,855||samples||9,634||11.8||21.2||2.5|||
|Bahrain||17 Apr 2021||3,887,079||samples||163,113||4.2||248||10.4|||
|Bangladesh||5 Mar 2021||4,119,031||samples||549,184||13.3||2.5||0.33|||
|Barbados||15 Apr 2021||147,866||samples||3,765||2.5||51.5||1.3|||
|Belarus||16 Apr 2021||5,627,834||samples||341,539||6.1||59.3||3.6|||
|Belgium||16 Apr 2021||11,907,015||samples||943,213||7.9||103.4||8.2|||
|Belize||15 Apr 2021||109,085||samples||12,529||11.5||26.7||3.1|||
|Benin||12 Apr 2021||575,088||7,611||1.3||4.9||0.065|||
|Bhutan||17 Apr 2021||661,950||samples||952||0.14||89.2||0.13|||
|Bolivia||16 Apr 2021||1,036,082||cases||287,360||27.7||9.1||2.5|||
|Bosnia and Herzegovina||16 Apr 2021||862,452||samples||188,994||21.9||25.2||5.5|||
|Botswana||13 Apr 2021||958,802||42,894||4.5||42.5||1.9|||
|Brazil||19 Feb 2021||23,561,497||samples||10,081,676||42.8||11.2||4.8|||
|Brunei||15 Apr 2021||117,619||samples||221||0.19||25.6||0.048|||
|Bulgaria||17 Apr 2021||2,357,428||samples||385,963||16.4||33.9||5.6|||
|Burkina Faso||4 Mar 2021||158,777||samples||12,123||7.6||0.76||0.058|||
|Burundi||5 Jan 2021||90,019||884||0.98||0.76||0.0074|||
|Cambodia||4 Apr 2021||724,812||2,689||0.37||4.5||0.017|||
|Cameroon||18 Feb 2021||942,685||samples||32,681||3.5||3.6||0.12|||
|Canada||17 Apr 2021||29,803,243||samples||1,113,907||3.7||78.6||2.9|||
|Chad||2 Mar 2021||99,027||samples||4,020||4.1||0.72||0.029|||
|Chile||16 Apr 2021||12,206,029||samples||1,109,311||9.1||64.0||5.8|||
|China[c]||31 Jul 2020||160,000,000||cases||87,655||0.055||11.1||0.0061|||
|Colombia||17 Apr 2021||13,774,899||samples||2,636,076||19.1||28.5||5.5|||
|Costa Rica||6 Apr 2021||842,015||samples||219,846||26.1||16.8||4.4|||
|Croatia||17 Apr 2021||1,693,080||cases||306,225||18.1||41.5||7.5|||
|Cuba||16 Apr 2021||3,341,813||samples||92,474||2.8||29.5||0.82|||
|Cyprus[d]||16 Apr 2021||4,224,159||samples||56,621||1.3||489||6.3|||
|Czechia||16 Apr 2021||6,524,970||samples||1,597,103||24.5||61.0||14.9|||
|Denmark[e]||16 Apr 2021||24,920,538||samples||241,007||0.97||428||4.1|||
|Djibouti||17 Apr 2021||143,650||10,412||7.2||15.6||1.1|||
|Dominica||1 Apr 2021||13,500||cases||165||1.2||18.8||0.23|||
|Dominican Republic||15 Apr 2021||1,363,804||samples||260,133||19.1||12.5||2.4|||
|DR Congo||28 Feb 2021||124,838||25,961||20.8||0.14||0.029|||
|Ecuador||17 Apr 2021||1,225,383||samples||358,157||29.2||7.2||2.1|||
|Egypt||9 Mar 2021||2,423,820||samples||187,716||7.7||2.4||0.19|||
|El Salvador||14 Apr 2021||881,245||samples||67,099||7.6||13.6||1.0|||
|Equatorial Guinea||12 Apr 2021||116,266||7,259||6.2||8.9||0.55|||
|Estonia||17 Apr 2021||1,224,645||samples||117,011||9.6||92.2||8.8|||
|Eswatini||13 Apr 2021||181,596||18,402||10.1||16.0||1.6|||
|Ethiopia||5 Mar 2021||2,165,507||samples||164,073||7.6||1.9||0.14|||
|Faroe Islands||16 Apr 2021||248,281||samples||662||0.27||476||1.3|||
|Fiji||17 Apr 2021||42,492||samples||72||0.17||4.7||0.0080|||
|Finland||15 Apr 2021||4,223,881||samples||83,253||2.0||76.2||1.5|||
|France[f][g]||17 Apr 2021||71,808,202||samples||5,260,182||7.3||110||8.1|||
|Gabon||5 Mar 2021||545,881||samples||15,517||2.8||1.8||0.050|||
|Gambia||15 Feb 2021||43,217||samples||4,469||10.3||2.0||0.21|||
|Georgia[h]||17 Apr 2021||2,191,531||samples||294,540||13.4||59.0||7.9|||
|Germany||14 Apr 2021||52,737,238||samples||3,044,016||5.8||62.9||3.6|||
|Ghana||30 Mar 2021||1,004,216||samples||90,674||9.0||3.2||0.29|||
|Greece||16 Apr 2021||7,379,458||samples||311,033||4.2||68.5||2.9|||
|Greenland||16 Apr 2021||21,610||samples||31||0.14||38.5||0.055|||
|Grenada||24 Mar 2021||23,989||155||0.65||21.5||0.14|||
|Guatemala||16 Apr 2021||1,161,896||samples||212,307||18.3||6.7||1.2|||
|Guinea||4 Apr 2021||412,164||samples||20,506||5.0||3.1||0.16|||
|Guinea-Bissau||1 Apr 2021||59,182||3,661||6.2||3.2||0.20|||
|Guyana||17 Apr 2021||107,093||cases||11,762||11.0||13.6||1.5|||
|Haiti||26 Mar 2021||58,922||cases||12,797||21.7||0.52||0.11|||
|Honduras||17 Apr 2021||579,874||samples||199,682||34.4||6.0||2.1|||
|Hungary||17 Apr 2021||5,096,421||samples||746,802||14.7||52.8||7.7|||
|Iceland||16 Apr 2021||568,908||samples||6,286||1.1||156||1.7|||
|India||17 Apr 2021||264,972,022||samples||14,526,609||5.5||19.2||1.05|||
|Indonesia||17 Apr 2021||13,776,810||cases||1,599,763||11.6||5.1||0.59|||
|Iran||16 Apr 2021||14,165,771||samples||2,194,133||15.5||17.0||2.6|||
|Iraq||17 Apr 2021||8,767,925||samples||970,987||11.1||21.8||2.4|||
|Ireland||16 Apr 2021||4,256,930||samples||242,819||5.7||86.5||4.9|||
|Israel||15 Apr 2021||13,929,118||samples||836,883||6.0||152||9.1|||
|Italy||17 Apr 2021||54,864328||samples||3,857,443||7.0||90.9||6.4|||
|Ivory Coast||3 Mar 2021||429,177||samples||33,285||7.8||1.6||0.13|||
|Jamaica||15 Apr 2021||311,749||samples||43,473||13.9||11.4||1.6|||
|Japan||1 Mar 2021||8,487,288||432,773||5.1||6.7||0.34|||
|Jordan||16 Apr 2021||6,448,333||samples||681,870||10.6||60.5||6.4|||
|Kazakhstan||17 Apr 2021||9,464,077||samples||284,173||3.0||50.7||1.5|||
|Kenya||5 Mar 2021||1,322,806||samples||107,729||8.1||2.8||0.23|||
|Kosovo||17 Apr 2021||496,611||cases||101,153||20.4||27.4||5.6|||
|Kuwait||17 Apr 2021||2,213,624||samples||255,860||11.6||51.6||6.0|||
|Kyrgyzstan||10 Feb 2021||695,415||samples||85,253||12.3||10.7||1.3|||
|Laos||1 Mar 2021||114,030||cases||45||0.039||1.6||0.00063|||
|Latvia||17 Apr 2021||2,071,140||samples||110,997||5.4||107.9||5.8|||
|Lebanon||17 Apr 2021||3,814,173||samples||508,503||13.3||55.9||7.5|||
|Lesotho||2 Apr 2021||68,712||10,707||15.6||3.4||0.53|||
|Liberia||4 Mar 2021||75,504||2,024||2.7||1.5||0.040|||
|Libya||15 Apr 2021||916,098||samples||171,131||18.7||13.3||2.5|||
|Lithuania||15 Apr 2021||2,606,339||samples||231,601||8.9||93.3||8.3|||
|Luxembourg[i]||15 Apr 2021||2,548,684||samples||64,746||2.5||407||10.3|||
|Madagascar||19 Feb 2021||119,608||cases||19,831||16.6||0.46||0.076|||
|Malawi||4 Apr 2021||220,384||samples||33,661||15.3||1.2||0.18|||
|Malaysia||16 Apr 2021||8,472,685||cases||370,528||4.4||25.9||1.1|||
|Maldives||16 Apr 2021||698,759||samples||26,021||3.7||178||6.6|||
|Mali||1 Mar 2021||200,772||samples||8,390||4.2||0.99||0.041|||
|Malta||17 Apr 2021||844,016||samples||29927||3.5||171||6.1|||
|Mauritania||16 Apr 2021||268,093||18,103||6.8||6.1||0.41|||
|Mauritius||22 Nov 2020||289,552||samples||494||0.17||22.9||0.039|||
|Mexico||3 Apr 2021||5,695,079||cases||2,249,195||39.5||4.4||1.7|||
|Moldova[j]||17 Apr 2021||939,938||samples||245,494||26.1||35.6||9.3|||
|Mongolia||13 Apr 2021||2,492,932||cases||16,603||0.67||74.3||0.50|||
|Montenegro||4 Aug 2020||24,469||cases||3,361||13.7||3.9||0.53|||
|Morocco||17 Apr 2021||6,157,491||cases||505,447||8.2||16.7||1.4|||
|Mozambique||31 Mar 2021||480,898||samples||67,579||14.1||1.5||0.22|||
|Myanmar||2 Apr 2021||2,540,584||samples||142,479||5.6||4.7||0.26|||
|Namibia||16 Apr 2021||368,930||samples||46,330||12.6||13.4||1.7|||
|Nepal||1 Mar 2021||2,165,985||samples||274,216||12.7||7.7||0.98|||
|Netherlands||13 Apr 2021||11,284,272||cases||1,364,025||12.1||64.8||7.8|||
|New Caledonia||16 Apr 2021||29,593||samples||123||0.42||10.9||0.045|||
|New Zealand||16 Apr 2021||1,963,982||samples||2,234||0.11||39.4||0.045|||
|Niger||22 Feb 2021||79,321||cases||4,740||6.0||0.35||0.021|||
|Nigeria||28 Feb 2021||1,544,008||samples||155,657||10.1||0.75||0.076|||
|North Korea||25 Nov 2020||16,914||cases||0||0||0.066||0|||
|North Macedonia||17 Apr 2021||688,876||samples||146,733||21.3||33.2||7.1|||
|Northern Cyprus[k]||17 Mar 2021||645,513||samples||3,913||0.61||198||1.2|||
|Norway||16 Apr 2021||4,967,185||samples||106,223||2.1||92.5||2.0|||
|Oman||28 Oct 2020||509,959||samples||114,434||22.4||11.0||2.5|||
|Pakistan||5 Mar 2021||9,173,593||samples||588,728||6.4||4.2||0.27|||
|Palestine||16 Apr 2021||1,670,034||samples||306,961||18.4||33.1||6.1|||
|Panama||17 Apr 2021||2,292,939||samples||360,597||15.7||54.9||8.6|||
|Papua New Guinea||17 Feb 2021||47,490||cases||961||2.0||0.53||0.011|||
|Paraguay||14 Apr 2021||994,694||samples||242,161||24.3||13.9||3.4|||
|Peru||17 Apr 2021||10,374,315||samples||1,697,626||16.4||31.6||5.2|||
|Philippines||16 Apr 2021||11,036,556||samples||914,971||8.3||10.9||0.91|||
|Poland||17 Apr 2021||13,335,088||samples||2,675,874||20.1||34.7||7.0|||
|Portugal||15 Apr 2021||9,608,064||samples||829,358||8.6||93.5||8.1|||
|Qatar||16 Apr 2021||1,830,688||cases||194,930||10.6||63.5||6.8|||
|Romania||29 Jan 2021||5,405,393||samples||724,250||13.4||27.9||3.7|||
|Russia||17 Apr 2021||125,486,939||samples||4,693,469||3.7||85.5||3.2|||
|Rwanda||17 Apr 2021||1,253,747||samples||23,866||1.9||9.7||0.18|||
|Saint Kitts and Nevis||15 Apr 2021||13,374||cases||44||0.33||25.5||0.084|||
|Saint Lucia||16 Apr 2021||38,495||samples||4,398||11.4||21.2||2.4|||
|Saint Vincent||14 Apr 2021||44,072||cases||1,818||4.1||40.0||1.6|||
|San Marino||16 Apr 2021||58,004||samples||5,016||8.6||169||14.7|||
|Saudi Arabia||17 Apr 2021||16,123,732||samples||404,054||2.5||46.3||1.2|||
|Senegal||5 Apr 2021||478,674||samples||39,093||8.2||3.0||0.25|||
|Serbia||17 Apr 2021||3,673,249||cases||660,229||18.0||52.7||9.5|||
|Singapore||12 Apr 2021||9,036,706||samples||60,719||0.67||158||1.1|||
|Slovakia||17 Apr 2021||2,486,691||samples||375,336||15.1||45.6||6.9|||
|Slovenia||15 Apr 2021||1,123,933||samples||230,828||20.5||53.7||11.0|||
|South Africa||17 Apr 2021||10,305,641||cases||1,565,680||15.2||17.4||0.3|||
|South Korea||1 Mar 2021||6,592,010||samples||90,029||1.4||12.7||0.17|||
|South Sudan||4 Mar 2021||113,686||8,527||7.5||0.89||0.067|||
|Spain||8 Apr 2021||44,285,495||samples||3,396,685||7.7||94.8||7.3|||
|Sri Lanka||30 Mar 2021||2,384,745||samples||93,128||3.9||10.9||0.43|||
|Sudan||7 Jan 2021||158,804||samples||23,316||14.7||0.36||0.053|||
|Sweden||12 Apr 2021||8,132,385||samples||872,712||10.7||78.7||8.5|||
|Switzerland[l]||16 Apr 2021||6,538,153||samples||632,399||9.7||75.9||7.3|||
|Taiwan[m]||3 Mar 2021||429,603||samples||955||0.22||1.8||0.0040|||
|Tanzania||18 Nov 2020||3,880||509||13.1||0.0065||0.00085|||
|Thailand||4 Mar 2021||1,579,597||cases||26,162||1.7||2.3||0.038|||
|Togo||4 Apr 2021||280,680||11,064||3.9||3.3||0.13|||
|Trinidad and Tobago||10 Apr 2021||115,591||cases||8,382||7.3||8.5||0.61|||
|Tunisia||15 Apr 2021||1,215,518||samples||281,777||23.2||10.3||2.4|||
|Turkey||17 Apr 2021||43,467,516||samples||4,212,645||9.7||52.3||5.1|||
|Uganda||11 Feb 2021||852,444||samples||39,979||4.7||1.9||0.087|||
|Ukraine||16 Apr 2021||8,869,518||samples||1,921,244||21.7||21.1||4.6|||
|United Arab Emirates||16 Apr 2021||41,349,068||samples||493,266||1.2||431||5.1|||
|United Kingdom||16 Apr 2021||140,944,028||samples||4,383,732||3.1||209||6.5|||
|United States||17 Apr 2021||414,763,751||samples||31,626,565||7.6||125||9.6|||
|Uruguay||16 Apr 2021||1,607,709||samples||159,569||9.9||46.3||4.6|||
|Uzbekistan||14 Jul 2020||1,400,000||samples||13,872||0.99||4.1||0.041|||
|Venezuela||30 Mar 2021||3,179,074||samples||159,149||5.0||11.0||0.55|||
|Vietnam||4 Apr 2021||2,809,181||samples||2,631||0.094||2.8||0.0027|||
|Zambia||17 Apr 2021||1,341,506||samples||90,844||6.8||7.7||0.52|||
|Zimbabwe||5 Mar 2021||392,323||samples||36,248||9.2||2.6||0.24|||
- 2002–2004 SARS outbreak
- Coronavirus breathalyzer
- Coronavirus disease 2019
- COVID-19 pandemic
- COVID-19 testing controversy in the Philippines
- "Coronavirus Disease 2019 (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 11 February 2020. Retrieved 9 June 2020.
- Kobokovich A, West R, Gronvall G. "Global Progress on COVID-19 Serology-Based Testing". Johns Hopkins Center for Health Security. Retrieved 9 June 2020.
- Kubina, Robert; Dziedzic, Arkadiusz (2020). "Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics". Diagnostics. 10 (6): 434. doi:10.3390/diagnostics10060434. PMC 7345211. PMID 32604919.
- "Test for Past Infection". U.S. Centers for Disease Control and Prevention (CDC). 2020. Archived from the original on 16 May 2020. Retrieved 19 May 2020.
Antibody blood tests, also called antibody tests, check your blood by looking for antibodies, which show if you had a previous infection with the virus. Depending on when someone was infected and the timing of the test, the test may not find antibodies in someone with a current COVID-19 infection.
- Abbasi J (April 2020). "The Promise and Peril of Antibody Testing for COVID-19". JAMA. 323 (19): 1881–83. doi:10.1001/jama.2020.6170. PMID 32301958. Retrieved 20 April 2020.
- Brotschi M (7 March 2020). "Bund sucht nicht mehr alle Corona-Infizierten" [The federal government is no longer looking for all those infected with corona]. Der Bund (in German). ISSN 0774-6156. Retrieved 9 June 2020.
- Van Beusekom, Mary (24 March 2020). "Italian doctors note high COVID-19 death rate, urge action". CIDRAP News. Retrieved 9 June 2020.
- Otmani M (22 March 2020). "COVID-19: First results of the voluntary screening in Iceland". Nordic Life Science. Retrieved 9 June 2020.
- Ward, D. (April 2020) "Sampling Bias: Explaining Wide Variations in COVID-19 Case Fatality Rates". WardEnvironment. doi: 10.13140/RG.2.2.24953.62564/1
- Henriques M (2 April 2020). "Coronavirus: Why death and mortality rates differ". BBC News. Retrieved 9 June 2020.
- Ward D (May 2020). Sampling Bias: Explaining Variations in Age Distributions of COVID-19 Cases. Technical Report (Report). WardEnvironment. doi:10.13140/RG.2.2.27321.19047/2.
- "Why More Younger People Are Testing Positive for COVID-19". Time. Retrieved 18 August 2020.
- Mina MJ, Parker R, Larremore DB (2020). "Rethinking Covid-19 Test Sensitivity – A Strategy for Containment". The New England Journal of Medicine. 383 (22): e120. doi:10.1056/NEJMp2025631. PMID 32997903. S2CID 222158786.
- "Siouxsie Wiles & Toby Morris: What we don't know about Covid-19". The Spinoff. 6 May 2020. Retrieved 6 May 2020.
- "Testing for COVID-19". U.S. Centers for Disease Control and Prevention (CDC). 20 May 2020. Archived from the original on 19 May 2020. Retrieved 20 May 2020.
Two kinds of tests are available for COVID-19: viral tests and antibody tests.
- Tanner, Tari (23 September 2020). "Finland deploys coronavirus-sniffing dogs at main airport". Associated Press. Helsinki. Retrieved 28 October 2020.
- Jones, Robert; Guest, Claire; Lindsay, Steve; Kleinschmidt, Immo; Bradley, John; Dewhirst, Sarah; et al. (12 August 2020). "Could bio-detection dogs be used to limit the spread of COVID-19 by travellers?". Journal of Travel Medicine. 27 (8). doi:10.1093/jtm/taaa131. ISSN 1708-8305. PMC 7454791. PMID 32789466. Retrieved 28 October 2020.
- Jendrny, Paula; Twele, Friederike; Meller, Sebastian; von Köckritz-Blickwede, Maren; Osterhaus, Albertus; Ebbers, Janek; et al. (23 July 2020). "Scent dog identification of samples from COVID-19 patients – a pilot study". BMC Infectious Diseases. 20 (1). 536. doi:10.1186/s12879-020-05281-3. ISSN 1471-2334. PMC 7376324. PMID 32703188. Retrieved 28 October 2020.
- Habibzadeh, Parham; Mofatteh, Mohammad; Silawi, Mohammad; Ghavami, Saeid; Faghihi, Mohammad Ali (17 February 2021). "Molecular diagnostic assays for COVID-19: an overview". Critical Reviews in Clinical Laboratory Sciences: 1–20. doi:10.1080/10408363.2021.1884640. ISSN 1549-781X. PMC 7898297. PMID 33595397.
- "RNA Extraction". AssayGenie. Retrieved 7 May 2020.
- "How is the COVID-19 Virus Detected using Real Time RT-PCR?". IAEA. 27 March 2020. Retrieved 5 May 2020.
- "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. (April 2009). "The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments". Clinical Chemistry. 55 (4): 611–22. doi:10.1373/clinchem.2008.112797. PMID 19246619.
- "Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis" (PDF). Clinical Science. 23 September 2005. Retrieved 5 May 2020.
- "The Basics: RT-PCR". ThermoFisher Scientific. Retrieved 5 May 2020.
- Kang XP, Jiang T, Li YQ, Lin F, Liu H, Chang GH, et al. (June 2010). "A duplex real-time RT-PCR assay for detecting H5N1 avian influenza virus and pandemic H1N1 influenza virus". Virology Journal. 7: 113. doi:10.1186/1743-422X-7-113. PMC 2892456. PMID 20515509.
- Joyce C (2002). Quantitative RT-PCR. A review of current methodologies. Methods Mol. Biol. 193. pp. 83–92. doi:10.1385/1-59259-283-X:083. ISBN 978-1-59259-283-8. PMID 12325527.
- Varkonyi-Gasic E, Hellens RP (2010). "qRT-PCR of Small RNAs". Plant Epigenetics. Methods in Molecular Biology. 631. pp. 109–22. doi:10.1007/978-1-60761-646-7_10. ISBN 978-1-60761-645-0. PMID 20204872.
- "Accelerated Emergency Use Authorization (Eua) Summary Covid-19 Rt-Pcr Test (Laboratory Corporation of America)". FDA. Retrieved 3 April 2020.
- Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M (April 2010). "A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines". Methods. 50 (4): S1-5. doi:10.1016/j.ymeth.2010.01.005. PMID 20215014.
- Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. (April 2009). "The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments". Clinical Chemistry. 55 (4): 611–22. doi:10.1373/clinchem.2008.112797. PMID 19246619.
- Dinnes J, Deeks JJ, Adriano A, Berhane S (2020). "Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection". Cochrane Database of Systematic Reviews. 8: CD013705. doi:10.1002/14651858.CD013705. PMID 32845525. S2CID 221326336.
- "Real-Time RT-PCR Panel for Detection 2019-nCoV". U.S. Centers for Disease Control and Prevention (CDC). 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
- Drosten C (26 March 2020). "Coronavirus-Update Folge 22" [Coronavirus update episode 22] (PDF). NDR. Archived (PDF) from the original on 31 March 2020. Retrieved 2 April 2020.
- "Here's where things stand on COVID-19 tests in the U.S." ScienceNews. 17 April 2020. Retrieved 6 May 2020.
- Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q (April 2020). "Saliva: potential diagnostic value and transmission of 2019-nCoV". International Journal of Oral Science. 12 (1): 11. doi:10.1038/s41368-020-0080-z. PMC 7162686. PMID 32300101.
- Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. (May 2003). "Identification of a novel coronavirus in patients with severe acute respiratory syndrome". The New England Journal of Medicine. 348 (20): 1967–76. doi:10.1056/NEJMoa030747. PMID 12690091.
- Ghoshal U, Vasanth S, Tejan N (2020). "A guide to laboratory diagnosis of Corona Virus Disease-19 for the gastroenterologists". Indian Journal of Gastroenterology. 39 (3): 236–242. doi:10.1007/s12664-020-01082-3. PMC 7462729. PMID 32875524.
- "COVID-19 saliva tests: What is the benefit?". Mayo Clinic. 16 April 2020. Retrieved 6 May 2020.
- "New Rutgers Saliva Test for Coronavirus Gets FDA Approval". Rutgers.edu. 13 April 2020. Retrieved 1 May 2020.
- "FDA authorizes Covid-19 saliva test for emergency use". CNN. 14 April 2020. Retrieved 1 May 2020.
- Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Ko AI (2020). "Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2". The New England Journal of Medicine. 383 (13): 1283–86. doi:10.1056/NEJMc2016359. PMC 7484747. PMID 32857487. S2CID 221358482.
- Service RF (2020). "Spit shines for easier coronavirus testing". Science. 369 (6507): 1041–42. Bibcode:2020Sci...369.1041S. doi:10.1126/science.369.6507.1041. PMID 32855317. S2CID 221358939.
- "Yale University School of Public Health finds saliva samples promising alternative to nasopharyngeal swab". Merck Manual. 29 April 2020. Retrieved 6 April 2020.
- "FDA gives emergency approval to 'game changer' COVID-19 saliva test". Retrieved 15 August 2020.
- "Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing". U.S. Food and Drug Administration (FDA) (Press release). 15 August 2020. Retrieved 6 November 2020.
- "Risk of False Results with the Curative SARS-Cov-2 Test for COVID-19". U.S. Food and Drug Administration (FDA). 4 January 2021. Retrieved 4 January 2021. This article incorporates text from this source, which is in the public domain.
- Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19 (2020) referenced
- CDC unpublished data
- COVID-19 Investigation Team (June 2020). "Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States". Nature Medicine. 26 (6): 861–68. doi:10.1038/s41591-020-0877-5. PMID 32327757.
- Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, et al. (March 2020). "Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore". JAMA. 323 (15): 1488–94. doi:10.1001/jama.2020.3204. PMC 7054855. PMID 32125362.
- Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. (March 2020). "SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients". The New England Journal of Medicine. 382 (12): 1177–79. doi:10.1056/NEJMc2001737. PMC 7121626. PMID 32074444.
- Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. (May 2020). "Virological assessment of hospitalized patients with COVID-2019". Nature. 581 (7809): 465–69. Bibcode:2020Natur.581..465W. doi:10.1038/s41586-020-2196-x. PMID 32235945.
- Zimmer C (5 May 2020). "With Crispr, a Possible Quick Test for the Coronavirus". The New York Times. ISSN 0362-4331. Retrieved 14 May 2020.
- "STOPCovid". stopcovid.science. Retrieved 14 June 2020.
- Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang MW, et al. (May 2020). "Point-of-care testing for COVID-19 using SHERLOCK diagnostics". MedRxiv: 2020.05.04.20091231. doi:10.1101/2020.05.04.20091231. PMC 7273289. PMID 32511521.
- "Developing Antibodies and Antigens for COVID-19 Diagnostics". Technology Networks. 6 April 2020. Retrieved 30 April 2020.
- Guglielmi G (2020). "Fast coronavirus tests: what they can and can't do". Nature. 585 (7826): 496–498. Bibcode:2020Natur.585..496G. doi:10.1038/d41586-020-02661-2. PMID 32939084. S2CID 221768935.
- "Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing". whitehouse.gov. 17 April 2020. Retrieved 30 April 2020 – via National Archives.
- "NIH launches competition to speed COVID-19 diagnostics". AAAS. 29 April 2020. Retrieved 1 May 2020.
- "What to know about the three main types of coronavirus tests". CNN. 29 April 2020. Retrieved 30 April 2020.
- "Rapid Tests". Rapid Tests.
- Shaw, Jonathan (3 August 2020). "Failing the Coronavirus-Testing Test". Harvard Magazine.
- Office of the Commissioner (9 May 2020). "Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients". FDA.
- Calvo-Henriquez, Christian; Maldonado-Alvarado, Byron; Chiesa-Estomba, Carlos; Rivero-Fernández, Irene; Sanz-Rodriguez, Marta; Villarreal, Ithzel María; Rodriguez-Iglesias, Miguel; Mariño-Sánchez, Franklin; Rivero-de-Aguilar, Alejandro; Lechien, Jerome R.; Martínez-Capoccioni, Gabriel (24 June 2020). "Ethyl alcohol threshold test: a fast, reliable and affordable olfactory Assessment tool for COVID-19 patients". European Archives of Oto-Rhino-Laryngology. 277 (10): 2783–2792. doi:10.1007/s00405-020-06131-3. ISSN 0937-4477. PMC 7312102. PMID 32583183.
- Menni, Cristina; Sudre, Carole H.; Steves, Claire J.; Ourselin, Sebastien; Spector, Tim D. (21 November 2020). "Widespread smell testing for COVID-19 has limited application – Authors' reply". The Lancet. 396 (10263): 1630–1631. doi:10.1016/S0140-6736(20)32316-3. ISSN 0140-6736. PMC 7832202. PMID 33157000.
- Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (July 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". AJR. American Journal of Roentgenology. 215 (1): 87–93. doi:10.2214/AJR.20.23034. PMID 32174129.
Known features of COVID-19 on initial CT include bilateral multilobar ground-glass opacification (GGO) with a peripheral or posterior distribution, mainly in the lower lobes and less frequently within the right middle lobe.
- Manigandan S, Wu M, Pugazhendhi A, Brindhadevi K (2020). "A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19". Process Biochemistry. 98: 233–40. doi:10.1016/j.procbio.2020.08.016. PMC 7439988. PMID 32843849.
- Lee EY, Ng MY, Khong PL (April 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet. Infectious Diseases. 20 (4): 384–85. doi:10.1016/S1473-3099(20)30134-1. PMC 7128449. PMID 32105641.
- "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020. Archived from the original on 13 May 2020. Retrieved 20 May 2020.
- "The next frontier in coronavirus testing: Identifying the full scope of the pandemic, not just individual infections". STAT. 27 March 2020. Retrieved 30 April 2020.
- Tang, E.W. (2020). "Testing for SARS-Cov-2 (COVID-19): A General Review". Rhode Island Medical Journal. 103 (8): 26–29. PMID 32900007 – via EBSCO.
- "What Immunity to COVID-19 Really Means". Scientific American. 10 April 2020. Archived from the original on 28 April 2020.
- Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. (June 2020). "Antibody tests for identification of current and past infection with SARS-CoV-2". The Cochrane Database of Systematic Reviews. 6: CD013652. doi:10.1002/14651858.CD013652. PMC 7387103. PMID 32584464. S2CID 220061130.
- "Cellex Emergency Use Authorization". FDA. 1 April 2020. Retrieved 10 April 2020.
- "Will an Antibody Test Allow Us to Go Back to School or Work?". The New York Times. 10 April 2020. Retrieved 15 April 2020.
- "Mount Sinai Emergency Use Authorization". FDA. 15 April 2020. Retrieved 18 April 2020.
- Bauer G (2020). "The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity)". Journal of Medical Virology. 93 (1): 311–322. doi:10.1002/jmv.26262. PMC 7361859. PMID 32633840.
- Ravi N, Cortade DL, Ng E, Wang SX (2020). "Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape". Biosensors and Bioelectronics. 165: 112454. doi:10.1016/j.bios.2020.112454. PMC 7368663. PMID 32729549.
- Goudouris ES (2020). "Laboratory diagnosis of COVID-19". Jornal de Pediatria. 97 (1): 7–12. doi:10.1016/j.jped.2020.08.001. PMC 7456621. PMID 32882235.
- "Global Progress on COVID-19 Serology-Based Testing". Johns Hopkins Center for Health Security. Retrieved 14 June 2020.
- "A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction". Research Square. 23 April 2020. Retrieved 28 April 2020.
- "Will antibody tests for the coronavirus really change everything?". Nature. 18 April 2020. Retrieved 20 April 2020.
- "Q&A on COVID-19 Antibody Tests". factcheck.org. 27 April 2020. Retrieved 28 April 2020.
- "Neutralising antibody". Biology-Online. 2008. Retrieved 4 July 2009.
- Schmaljohn AL (July 2013). "Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts". Current HIV Research. 11 (5): 345–53. doi:10.2174/1570162x113116660057. PMID 24191933.
- "Virus neutralization by antibodies". Virology Blog. 24 July 2009. Retrieved 29 April 2020.
- "expert reaction to announcement by Roche of its new serology test for COVID-19 antibodies". Science Media Centre. 17 April 2020. Retrieved 28 April 2020.
- Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH (September 2007). "Disappearance of antibodies to SARS-associated coronavirus after recovery". The New England Journal of Medicine. NEJM. 357 (11): 1162–63. doi:10.1056/NEJMc070348. PMID 17855683.
- "Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study" (PDF). Journal of Immunology. 19 April 2011. Retrieved 1 May 2020.
- Leslie M (May 2020). "T cells found in coronavirus patients 'bode well' for long-term immunity". Science. 368 (6493): 809–10. Bibcode:2020Sci...368..809L. doi:10.1126/science.368.6493.809. PMID 32439770. S2CID 218834495.
- Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19 (2020) referenced
- CDC unpublished data
- Young et al. (2020)
- Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19 (2020) referenced
- Roser M, Ritchie H, Ortiz-Ospina E (4 March 2020). "Coronavirus Disease (COVID-19) – Statistics and Research". Our World in Data – via ourworldindata.org.
- Schnirring, Lisa (11 January 2020). "China releases genetic data on new coronavirus, now deadly". CIDRAP. Archived from the original on 11 January 2020. Retrieved 12 January 2020.
- Shu Y, McCauley J (March 2017). "GISAID: Global initiative on sharing all influenza data – from vision to reality". Euro Surveillance. 22 (13). doi:10.2807/1560-7917.ES.2017.22.13.30494. PMC 5388101. PMID 28382917.
- Ioannidis, John P.A. (17 March 2020). "A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data". STAT. Retrieved 22 March 2020.
- "'Test, Test, Test': WHO Chief's Coronavirus Message to World". The New York Times. Reuters. 16 March 2020. Archived from the original on 20 March 2020. Retrieved 16 March 2020.
- Farge E, Revill J (17 March 2020). "'Test, test, test': WHO chief's coronavirus message to world". Reuters. Retrieved 6 November 2020.
- "Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK" (PDF). European Centre for Disease Prevention and Control. 25 March 2020. pp. 15–16. Retrieved 29 March 2020.
the current shortages of laboratory consumables and reagents affect diagnostic capacity and hamper the epidemic response at the national and local levels. The laboratories have experienced delayed or missing deliveries of swabbing material, plastic consumables, RNA extraction and RT-PCR reagents, and PPE. This is affecting laboratories in all EU/EEA countries.
- Baird RP (24 March 2020). "Why Widespread Coronavirus Testing Isn't Coming Anytime Soon". The New Yorker. Archived from the original on 28 March 2020. Retrieved 29 March 2020.
South Dakota, said that her state's public-health laboratory—the only lab doing COVID-19 testing in the state—had so much trouble securing reagents that it was forced to temporarily stop testing altogether. also noted critical shortages of extraction kits, reagents, and test kits
- Ossola A (25 March 2020). "Here are the coronavirus testing materials that are in short supply in the US". Quartz. Archived from the original on 26 March 2020. Retrieved 29 March 2020.
extract the virus's genetic material—in this case, RNA—using a set of chemicals that usually come in pre-assembled kits. 'The big shortage is extraction kits' There are no easy replacements here: 'These reagents that are used in extraction are fairly complex chemicals. They have to be very pure, and they have to be in pure solution'
- Temple-Raston, Dina (6 November 2020). "CDC Report: Officials Knew Coronavirus Test Was Flawed But Released It Anyway". NPR. Retrieved 20 March 2021.
- Armario, Christine (7 October 2020). "Peru bet heavily on cheap COVID tests; it didn't go well". Associated Press. Retrieved 20 March 2021.
- email@example.com, Jeff Kiger. "Mayo Clinic starts drive-thru testing for COVID-19". PostBulletin.com. Retrieved 13 March 2020.
- Hawkins, Andrew J. (11 March 2020). "Some states are offering drive-thru coronavirus testing". The Verge. Retrieved 13 March 2020.
- "South Korea's Drive-Through Testing For Coronavirus Is Fast – And Free". npr. 11 March 2020. Retrieved 16 March 2020.
- "In Age of COVID-19, Hong Kong Innovates To Test And Quarantine Thousands". NPR.org.
- "Pooling method allows dozens of COVID-19 tests to run simultaneously". medicalxpress.com. Retrieved 24 March 2020.
- "Israeli team has coronavirus test kit to test dozens of people at once". The Jerusalem Post | JPost.com. Retrieved 24 March 2020.
- Israel21c Staff (19 March 2020). "Israelis introduce method for accelerated COVID-19 testing". Israel21c. Retrieved 24 March 2020.
- "We 'pool' coronavirus samples to test 1,000s at a go; we've done 30,000 since Sunday – Noguchi". GhanaWeb. 22 April 2020. Retrieved 22 April 2020.
- "Pooling samples boosts Ghana's COVID-19 testing". WHO Africa. 31 July 2020. Retrieved 31 July 2020.
- "Pooling samples boosts Ghana's COVID-19 testing". World Health Organization. 30 July 2020. Retrieved 30 July 2020.
- "[Coronavirus] Verified 'sample pooling' introduced to prevent herd infection in S. Korea". ajudaily.com. 9 April 2020. Retrieved 19 April 2020.
- "Gov. Ricketts provides update on coronavirus testing". KMTV. 24 March 2020. Retrieved 19 April 2020.
- May 2020, Nicoletta Lanese. "Wuhan tested millions of people for COVID-19 in just days. Could US cities do the same?". livescience.com. Retrieved 28 June 2020.
- "Latest coronavirus update: UP to begin 'pool testing' of Covid suspects". Free Press Journal. Retrieved 19 April 2020.
- Sumati Yengkhom. "West Bengal to start pool testing of samples in low-risk zones". The Times of India. Retrieved 19 April 2020.
- "Punjab launches pool testing". Retrieved 19 April 2020.
- "'Chhattisgarh to adopt pool sample testing': Health minister TS Singh Deo on Covid-19". Hindustan Times. 15 April 2020. Retrieved 19 April 2020.
- "Maharashtra to go for pool testing to defeat coronavirus". Deccan Herald. 12 April 2020. Retrieved 19 April 2020.
- "Origami Assays". Origami Assays. 2 April 2020. Retrieved 7 April 2020.
- Pulia MS, O'Brien TP, Hou PC, Schuman A, Sambursky R (August 2020). "Multi-tiered screening and diagnosis strategy for COVID-19: a model for sustainable testing capacity in response to pandemic". Annals of Medicine. 52 (5): 207–14. doi:10.1080/07853890.2020.1763449. PMC 7877955. PMID 32370561. S2CID 218519851.
- "Which States Are Doing Enough Testing? This Benchmark Helps Settle The Debate". NPR.org. 22 April 2020. Retrieved 11 May 2020.
- Lee, Timothy B. (2 April 2020). "America's COVID-19 testing has stalled, and that's a big problem". Ars Technica.
- Romer P. "Roadmap to responsibly reopen America" (PDF). Retrieved 11 May 2020.
- "ROADMAP TO PANDEMIC RESILIENCE" (PDF). Edmond J. Safra Center for Ethics. 20 April 2020. Retrieved 19 May 2020.
- "Certified Service Providers". Pacific Biosciences. Retrieved 18 May 2020.
- "Service Provider Program – US". www.thermofisher.com. ThermoFisher Scientific. Retrieved 18 May 2020.
- "Paul Romer". paulromer.net. Simulating Covid-19: Part 2. Retrieved 19 May 2020.
- "[NEW PRODUCT] COVID-19 KIT". kogene.co.kr. 27 February 2020. Archived from the original on 23 April 2020.
- "Letter from FDA". FDA. 27 March 2020. Retrieved 2 April 2020.
- ID NOW COVID-19, Instruction for Use, FDA
- "The scramble for the rapid coronavirus tests everybody wants". The Washington Post. 1 April 2020.
- "FDA issues emergency approval of new antigen test that is cheaper, faster and simpler". The Washington Post. 9 May 2020.
- Sofia 2 SARS Antigen FIA Instructions for Use, FDA.gov
- "NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection | NIH: National Institute of Allergy and Infectious Diseases". niaid.nih.gov. Retrieved 11 April 2020.
- Mandavilli A, Thomas K (10 April 2020). "Will an Antibody Test Allow Us to Go Back to School or Work?". The New York Times. Retrieved 11 April 2020.
- "Quest Diagnostics Launches Consumer-Initiated COVID-19 Antibody Test Through QuestDirect™". Quest Diagnosics. 28 April 2020.
- Fellmann F. (March 2020). (in German) "Jetzt beginnt die Suche nach den Genesenen". Tages Anzeiger. Retrieved 28 March 2020.
- "Quotient Limited". quotientbd.com. Retrieved 10 May 2020.
- "Quotient Limited Receives CE Mark for Its SARS-CoV-2 (COVID-19) Antibody Microarray". HospiMedica. Retrieved 6 May 2020.
- Strassheim, Isabel. "Antikörper-Nachweis zugelassen: Schweizer Start-up zieht bei Covid-Test mit Roche gleich" [Antibody detection approved: Swiss start-up draws level with Roche in Covid test]. Tages Anzeiger. Retrieved 25 May 2020.
- "EUA Authorized Serology Test Performance". U.S. Food and Drug Administration (FDA). 7 May 2020. Retrieved 8 May 2020.
- Bastos, Mayara Lisboa; Tavaziva, Gamuchirai; Abidi, Syed Kunal; Campbell, Jonathon R.; et al. (1 July 2020). "Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis". BMJ. 370: m2516. doi:10.1136/bmj.m2516. ISSN 1756-1833. PMC 7327913. PMID 32611558.
- Spencer, Elizabeth; Henighan, Carl (1 September 2020). "Overview of BMJ: Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis". CEBM. Retrieved 24 September 2020.
- Spencer, Elizabeth; Jefferson, Tom; Brassey, Jon; Heneghan, Carl (11 September 2020). "When is Covid, Covid?". CEBM. Retrieved 19 September 2020.
- Jefferson, Tom; Spencer, Elizabeth; Brassey, Jon; Heneghan, Carl (3 September 2020). "Viral cultures for COVID-19 infectivity assessment. Systematic review". MedRxiv: 2020.08.04.20167932. doi:10.1101/2020.08.04.20167932. S2CID 220962177.
- Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (March 2020). "Detection of SARS-CoV-2 in Different Types of Clinical Specimens". JAMA. 323 (18): 1843–44. doi:10.1001/jama.2020.3786. PMC 7066521. PMID 32159775.
- Ferran, Maureen (7 May 2020). "COVID-19 tests are far from perfect, but accuracy isn't the biggest problem". Popular Science. Retrieved 10 May 2020.
- "Serological testing for SARS-CoV-2 antibodies". American Medical Association. 14 May 2020. Retrieved 29 May 2020.
- "Interim Guidelines for COVID-19 Antibody Testing". U.S. Centers for Disease Control and Prevention (CDC). 23 May 2020. Retrieved 29 May 2020.
- Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J (August 2020). "Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure". Annals of Internal Medicine. 173 (4): 262–67. doi:10.7326/M20-1495. PMC 7240870. PMID 32422057.
- "RT-PCR Testing". www.idsociety.org. Retrieved 16 February 2021.
- "Comparing RT-PCR and Chest CT for Diagnosing COVID-19". HCPLive®. Retrieved 23 May 2020.
- "Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19". U.S. Centers for Disease Control and Prevention (CDC). 30 April 2020.
- Xiao AT, Tong YX, Zhang S (April 2020). "Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients". Clinical Infectious Diseases. 71 (16): 2249–2251. doi:10.1093/cid/ciaa460. PMC 7188124. PMID 32306036.
- Engelmann I, Alidjinou EK, Ogiez J, Szunerits S (2021). "Preanalytical Issues and Cycle Threshold Values in SARS-CoV-2 Real-Time RT-PCR Testing: Should Test Results Include These?". ACS Omega. 6 (10): 6528–6536. doi:10.1021/acsomega.1c00166. PMC 7970463. PMID 33748564.
- van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, et al. (July 2020). "Comparison of seven commercial RT-PCR diagnostic kits for COVID-19". Journal of Clinical Virology. 128: 104412. doi:10.1016/j.jcv.2020.104412. PMC 7206434. PMID 32416600.
- "Chinese Covid-19 test kit outstrips alternatives in Dutch study". South China Morning Post. 20 May 2020. Retrieved 23 May 2020.
- Heneghan, Carl; Jefferson, Tom (1 September 2020). "Virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR". CEBM. Retrieved 19 September 2020.
- Lu, Jing; Peng, Jinju; Xiong, Qianling; Liu, Zhe; et al. (31 July 2020). "Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR". EBioMedicine. 59: 102960. doi:10.1016/j.ebiom.2020.102960. PMC 7444471. PMID 32853988.
- Spencer, Elizabeth; Jefferson, Tom; Brassey, Jon; Heneghan, Carl (11 September 2020). "When is Covid, Covid?". The Centre for Evidence-Based Medicine. Retrieved 19 September 2020.
- "SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence". GOV.UK. Retrieved 19 September 2020.
- "Study Raises Questions About False Negatives From Quick COVID-19 Test". NPR. 21 April 2020. Retrieved 1 May 2020.
- Thomas, Katie (13 May 2020). "Coronavirus Testing Used by the White House Could Miss Infections". The New York Times. ISSN 0362-4331. Retrieved 14 May 2020.
- "National laboratories". who.int.
- "PHE novel coronavirus diagnostic test rolled out across UK". GOV.UK. Retrieved 12 April 2020.
In addition to processing samples from suspected cases in this country, PHE is now working as a reference laboratory for WHO, testing samples from countries that do not have assured testing capabilities.
- "Specimen referral for COVID-19 – operational details of WHO reference laboratories providing confirmatory testing for COVID-19" (PDF). World Health Organization. Retrieved 29 March 2020.
- "COVID-19: First results of the voluntary screening in Iceland". Nordic Life Science. 27 March 2020. Retrieved 5 April 2020.
- "How an experiment helped one Italian town find 'submerged infections,' cut new COVID-19 cases to zero". National Post. 19 March 2020.
- "PCR拡充が必要 専門家会議が会見 (全文1)" [PCR expansion required Expert meeting (Full text 1)]. THE PAGE (in Japanese). Yahoo!ニュース. 5 May 2020. p. 5. Retrieved 27 May 2020.
- "「新型コロナウイルス感染拡大阻止 最前線からの報告" [Report from the front line to prevent the spread of new coronavirus infection]. NHK (in Japanese). 15 April 2020. Retrieved 27 May 2020.
- "Did Japan Just Beat the Virus Without Lockdowns or Mass Testing?". Bloomberg. 23 May 2020. Retrieved 27 May 2020.
- "PCR拡充が必要 専門家会議が会見 (全文1)" [PCR expansion required Expert meeting (Full text 1)]. THE PAGE (in Japanese). Yahoo!ニュース. 5 May 2020. p. 3. Retrieved 27 May 2020.
- "新型コロナウイルス 感染爆発をどう防ぐか" [How to prevent the outbreak of new coronavirus infection]. NHK (in Japanese). 8 April 2020. Retrieved 27 May 2020.
- "第1波は終息するも欧米からの帰国者経由の第2波が拡大" [The first wave is over, but the second wave is expanding via returnees from Europe and the United States]. 日経メディカル (Nikkei Medical) (in Japanese). 12 May 2020. Retrieved 27 May 2020.
- "専門家に聞く"新型コロナウイルス"との闘い方と対策" [Ask experts how to fight the "new coronavirus" and countermeasures]. NHK (in Japanese). 27 March 2020. Retrieved 27 May 2020.
- "新型コロナ抗原検査キット、13日から実用化 加藤厚労相が発表 PCRとの併用を想定" [New corona antigen test kit put into practical use from 13th. Minister of Health, Labor and Welfare Kato announced that it will be used in combination with PCR]. 毎日新聞 (Mainichi newspaper ) (in Japanese). 12 May 2020. Retrieved 27 May 2020.
- "コロナ抗原検査が使用可能に、陽性のみ確定診断" [Corona antigen test available, positive only definitive diagnosis]. 日経メディカル (Nikkei Medical) (in Japanese). 12 May 2020. Retrieved 15 May 2020.
- "PCR拡充が必要 専門家会議が会見 (全文1)" [PCR expansion required Expert meeting (Full text 1)]. THE PAGE (in Japanese). Yahoo!ニュース. 5 May 2020. p. 4. Retrieved 27 May 2020.
- "クルーズ船112人治療で「院内感染」ゼロ!「自衛隊中央病院」はなぜ奇跡を起こせたのか" [No "nosocomial infection" with treatment of 112 cruise ships! Why did "Self-Defense Forces Central Hospital" cause a miracle?]. 週刊新潮 (Shukan Shincho) (in Japanese). 30 April 2020. Retrieved 27 May 2020.
- "「PCR検査数少ないが、死亡者数・率低い」専門家会議" ["The number of PCR tests is small, but the number of deaths and rate is low" Expert meeting]. m3.com (in Japanese). 5 May 2020. Retrieved 27 May 2020.
- "調査報告クルーズ船 ウイルス対策のカギは?" [Survey Report What is the key to anti-virus measures for cruise ships?]. NHK (in Japanese). 7 May 2020. Retrieved 24 May 2020.
- "新型コロナウイルス感染症の現在の状況と厚生労働省の対応について（令和２年７月20日版）" [Current status of new coronavirus infection and response by the Ministry of Health, Labor and Welfare (Reiwa 20 July, 2nd edition)] (in Japanese). 厚生労働省. 20 July 2000. Retrieved 1 August 2020.
- "PCR検査能力、4月の3倍 それでも受けにくいわけは" [PCR test capacity, 3 times that of April]. Asahi Shimbun (in Japanese). 28 July 2020. Retrieved 1 August 2020.
- "日本のコロナ検査能力、米英の1割どまり" [Japan's corona inspection ability, only 10% of the US and UK] (in Japanese). The Nikkei. 21 July 2020. Retrieved 1 August 2020.
- "新型コロナが弱毒化しているという根拠はない" [There is no evidence that the new corona is attenuated] (in Japanese). Yahoo!ニュース. 26 July 2020. Retrieved 1 August 2020.
- "軽症者施設、23都府県で不足 コロナ第2波推計" [Facility for mildly ill people, Insufficient in 23 prefectures Corona second wave estimation] (in Japanese). The Nikkei. 21 July 2020. Retrieved 1 August 2020.
- "患者急増、埋まりつつあるベッド 増床要請に頭抱える病院…スタッフは?一般患者は?経営は?" [The number of patients is increasing rapidly, and the beds are being filled up. Hospitals are having a request to increase the floor space ... Staff? General patients? Management?]. Mainichi Shimbun (in Japanese). 22 July 2020. Retrieved 1 August 2020.
- "軽症患者ＩＣＵを圧迫 クラスターはほぼ終息 新型コロナで兵庫県対策協" [Squeezing ICU for mildly ill patients The cluster is almost over With the new corona] (in Japanese). 神戸新聞. 25 March 2020. Retrieved 1 August 2020.
- "Over 3 mln COVID-19 tests conducted in Russia". TASS. 27 April 2020. Archived from the original on 11 May 2020. Retrieved 29 April 2020.
- "Popova said explosive growth in incidence was not allowed due to measures taken". TASS. 28 April 2020. Retrieved 29 April 2020.
- "COVID-19 outbreak: Petition to close schools in Singapore garners 7,700 signatures to date". msn.com.
- "More than 3.6 million people tested during the weekend". The Slovak Spectator. 1 November 2020.
- Kuhn, Anthony (12 March 2020). "Experts Credit South Korea's Extensive Testing For Curbing Coronavirus Spread". NPR.org. Retrieved 28 June 2020.
- "日本が韓国の新型コロナウイルス対策から学べること──（1）検査体制" [What Japan can learn from Korea's measures against the new coronavirus ── (1) Inspection system]. Newsweek Japan (in Japanese). 2 April 2020. Retrieved 5 June 2020.
- "日本が韓国の新型コロナウイルス対策から学べること──（3）情報公開" [What Japan can learn from Korea's measures against the new coronavirus ── (3) Information disclosure]. Newsweek Japan (in Japanese). 21 April 2020. Retrieved 5 June 2020.
- "日本が韓国の新型コロナウイルス対策から学べること──（4）軽症者の隔離・管理対策：「生活治療センター」" [What Japan can learn from Korea's measures against the new coronavirus ── (4) Isolation and management measures for mildly ill people: "Life Treatment Center"]. Newsweek Japan (in Japanese). 11 May 2020. Retrieved 5 June 2020.
- "韓国のコロナ対策を称える日本に欠ける視点" [Japan's lack of perspective to praise South Korea's measures against corona]. Newsweek Japan (in Japanese). 2 May 2020. Retrieved 5 June 2020.
- "韓国式大量検査は徴兵制の賜物…新型コロナが揺さぶる「自由」の価値" [Korean-style mass inspection is a gift of conscription ... The value of "freedom" that the new corona shakes] (in Japanese). FNNプライム. 14 April 2020. Retrieved 5 June 2020.
- "韓国における新型コロナウィルス防疫事情（韓国）" [New Coronavirus Epidemic Prevention Circumstances in South Korea (Korea)] (in Japanese). 日本商工会議所. 10 May 2020. Retrieved 5 June 2020.
- "韓国製PCR検査キットが新型コロナから世界を救う日" [The day when the Korean PCR test kit saves the world from the new corona]. Newsweek Japan (in Japanese). 14 April 2020. Retrieved 5 June 2020.
- "新型ウイルス"パンデミック" 医療崩壊を防ぐには" [New virus "pandemic" How to prevent medical collapse]. NHK (in Japanese). 9 April 2020. Retrieved 2 June 2020.
- "IT活用でコロナ追跡 韓国、感染者の経路公開" [Corona tracking by utilizing IT South Korea, route disclosure of infected people]. Mainichi Shimbun (in Japanese). 16 April 2020. Retrieved 5 June 2020.
- "コロナ対策で浮かび上がる「監視社会」韓国 個人情報をここまでさらしてよいのか" ["Surveillance society" that emerges from corona measures Can South Korea expose personal information to this extent?]. Tokyo Shimbun (in Japanese). 1 April 2020. Retrieved 5 June 2020.
- "新型コロナ：「感染追跡」デジタル監視とプライバシーの新しい日常" [New Corona: "Infection Tracking" New Everyday Life in Digital Surveillance and Privacy] (in Japanese). Yahoo!ニュース. 26 March 2020. Retrieved 5 June 2020.
- "韓国、コロナ隔離者に監視腕輪 「人権侵害」の声" [South Korea, Corona quarantine voice of surveillance bracelet "human rights violations"] (in Japanese). The Nikkei. 17 April 2020. Retrieved 29 May 2020.
- "South Korea is watching quarantined citizens with a smartphone app". MIT Technology Review. 6 March 2020. Retrieved 5 June 2020.
- "Coronavirus privacy: Are South Korea's alerts too revealing?". BBC. 5 March 2020. Retrieved 5 June 2020.
- "台湾がコロナ｢優等生｣になった理由。閣僚に医師出身、デジタル化の一方で強まる監視" [The reason why Taiwan became a corona "honor student". A doctor from a minister, increasing surveillance while digitizing]. Business Insider (in Japanese). 1 May 2020. Retrieved 6 June 2020.
- "台湾の新型コロナ対策が「善戦」しているワケ" [The reason why Taiwan's new corona measures are "good fight"]. Wedge Infinity (in Japanese). 28 February 2020. Retrieved 6 June 2020.
- "台湾が新型コロナの感染拡大を抑制できている理由" [Why Taiwan is able to curb the spread of the new corona]. Wedge Infinity (in Japanese). 28 February 2020. Retrieved 6 June 2020.
- "新型コロナ対応の「優等生」は「台湾・韓国・ドイツ」" [Why Taiwan is able to curb the spread of the new corona ...] (in Japanese). 日経ビジネス (Nikkei Business). 21 April 2020. Retrieved 6 June 2020.
- "Covid-19: Denmark suspends flights from the Emirates". Le Figaro. Retrieved 22 January 2021.
- "COVID-19 Public Policies #2 ニューヨークはいかにして検査数を増やしたのか" [COVID-19 Public Policies #2 How New York increased the number of inspections]. Office of the City of Yokohama Representative to the Americas (in Japanese). 14 May 2020. Retrieved 2 June 2020.
- "Coronavirus New York: health officials provide limits on testing patients for COVID-19". Eyewitness News. 21 March 2020. Retrieved 2 June 2020.
- "マスクも防護服も足りない! ニューヨークの病院で看護師が新型コロナウイルスに感染、死亡" [Not enough masks and protective clothing! A nurse is infected with a new coronavirus and dies at a hospital in New York]. Business Insider Japan (in Japanese). 27 March 2020. Retrieved 2 June 2020.
- "NY州感染者数、全米2位に 感染爆発で2週間封じ込め作戦へ" [The number of infected people in New York ranks second in the United States.]. Yahoo!ニュース (in Japanese). 11 March 2020. Retrieved 2 June 2020.
- "Coronavirus clue? Most cases aboard U.S. aircraft carrier are symptom-free". Reuters. 16 April 2020.
- "Sailors on sidelined USS Theodore Roosevelt get virus for second time". NBC News. Retrieved 21 May 2020.
- "Special Report: Italy and South Korea virus outbreaks reveal disparity in deaths and tactics". Reuters. 13 March 2020. Retrieved 22 June 2020.
- "Want to know how many people have the coronavirus? Test randomly". The Conversation. 13 April 2020. Retrieved 7 May 2020.
- "M&E – Health Information System General Directorate – National Diseases Surveillance and Response". MoPH Data Warehouse – Dashboard. 17 December 2020.
- "COVID19/ Ministria e Shëndetësisë: 736 të vaksinuar, 3935 testime, 991 të shëruar, 1112 raste të reja dhe 17 humbje jete në 24 orët e fundit". Ministria e Shëndetësisë dhe Mbrojtjes Sociale [Ministry of Health and Social Protection] (in Albanian). 18 February 2021.
- "Coronavirus Disease 2019 (COVID-19)". Africa CDC.
- "Documentation: RAPPORT DE SITUATION SUR L'EPIDEMIE DE CORONAVIRUS COVID-19". Ministère de la Santé de la Population et de la Réforme Hospitalière (MSPRH) [Ministry of Health, Population and Hospital Reform] (in French). 2 November 2020.
- "COVID-19 Dashboard". Government of Andorra. 14 April 2021.
- "COVID-19: ANGOLA COM 58 NOVAS INFECÇÕES E 44 RECUPERADOS". Agência Angola Press (in Portuguese). 4 March 2021.
- "COVID-19 Antigua & Barbuda Dashboard". Official Facebook page of the Ministry of Health & The Environment, Antigua and Barbuda. 6 March 2021.
- "Sala de Situaciόn Coronavirus online" (PDF). Argentina.gob.ar (in Spanish). 16 April 2021.
- Կորոնավիրուսային հիվանդություն (COVID-19). Հիվանդությունների վերահսկման և կանխարգելման ազգային կենտրոն [National Center for Disease Control and Prevention] (in Armenian). 17 April 2021.
- "Coronavirus (COVID-19) current situation and case numbers". Department of Health. 16 April 2021.
- "Coronavirus". AGES Dashboard COVID19 (in German). 16 April 2021.
- "AZƏRBAYCANDA CARİ VƏZİYYƏT". Azərbaycan Respublikasının Nazirlər Kabineti [Cabinet of Ministers of the Republic of Azerbaijan] (in Azerbaijani). 17 April 2021.
- "News and Press Releases: COVID-19 Report Update". Government of the Bahamas. 15 April 2021.
- الموقع الرسمي للمستجدات الصحية، مملكة البحرين. وزارة الصحة [Ministry of Health] (in Arabic). 17 April 2021.
- "Bangladesh Covid-19 Update". Institute of Epidemiology, Disease Control and Research. 5 March 2021.
- "COVID-19 Update". Barbados Government Information Service. 16 April 2021.
- Официальный Минздрав. Официальный канал Министерства здравоохранения Республики Беларусь [Telegram channel of the Ministry of Health of the Republic of Belarus] (in Russian). 16 April 2021.
- "Epistat COVID19 Belgian Dashboard". Sciensano. 17 April 2021.
- "COVID-19 UPDATE". Facebook account of the Ministry of Health and Wellness Belize. 15 April 2021.
- "Informations coronavirus (covid-19)". Gouvernement de la République du Bénin [Government of the Republic of Benin] (in French). 12 April 2021.
- "National Situational Update on COVID-19". Ministry of Health. 17 April 2021.
- "REPORTE COVID-19 EN BOLIVIA". Ministerio de Salud [Ministry of Health] (in Spanish). 16 April 2021.
- "Službene informacije o koronavirusu u BiH". Ministarstvo civilnih poslova Bosne i Hercegovine [Ministry of Civil Affairs of Bosnia and Herzegovina] (in Bosnian). 16 April 2021.
- "COVID-19 Botswana Dashboard". Government of Botswana. 13 April 2021.
- "BW government on Facebook". Government of Botswana. 3 December 2020.
- "COVID-19 Testes". Ministério da Saúde [Ministry of Health] (in Portuguese). 19 February 2021.
- "Coronavírus Brasil". Ministério da Saúde [Ministry of Health] (in Portuguese). 19 February 2021.
- "PRESS RELEASE ON THE CURRENT SITUATION OF THE COVID-19 INFECTION IN BRUNEI DARUSSALAM". Ministry of Health Brunei Darussalam. 15 April 2021.
- COVID-19: Единен информационен портал. COVID-19: Единен информационен портал [COVID-19: United information portal] (in Bulgarian). 18 April 2021.
- "Communiqué Coronavirus (COVID-19) au Burkina Faso". Facebook account of the Service d'Information du Gouvernement (SIG) [Government Information Service] (in French). 5 March 2021.
- "Update on COVID-19". Facebook account of the Ministère de la Santé Publique Burundi [Ministry of Public Health Burundi] (in French). 5 January 2021.
- បច្ចុប្បន្នភាពនៃជំងឺកូរ៉ូណាថ្មី COVID-19 នៅប្រទេសកម្ពុជា. Communicable Disease Control Department, Ministry of Health (Cambodia) (in Khmer). 4 April 2021.
- "Coronavirus disease (COVID-19): Outbreak update". Government of Canada. Retrieved 17 April 2021.
- "COMMUNIQUÉ N*320 DE LA COORDINATION NATIONALE DE RIPOSTE SANITAIRE". Official Facebook account of the Ministère de la Santé Publique du Tchad [Ministry of Public Health of Chad] (in French). 2 March 2021.
- "Cifras Oficiales: COVID-19". Gobierno de Chile [Government of Chile] (in Spanish). 16 April 2021.
- 我国核酸日检测能力达484万份. 中华人民共和国中央人民政府 [The Central People's Government of the People's Republic of China] (in Chinese). 6 August 2020.
- "Aug 1: Daily briefing on novel coronavirus cases in China". National Health Commission of the People's Republic of China. 1 August 2020.
- "#COVID19 en Colombia 28-01-2021". Instituto Nacional de Salud de Colombia [Colombia's National Institute of Health] (in Spanish). 17 January 2021.
- "#ReporteCOVID19". Cuenta Oficial del Ministerio de Salud y Protección Social de Colombia [Official Account of Health and Social Protection Ministry of Columbia] (in Spanish). 17 April 2021.
- "Situación Nacional COVID-19". Geovisión; Ministerio de Salud, Costa Rica [Ministry of Health, Costa Rica] (in Spanish). 6 April 2021.
- "xxx novih slučajeva u protekla 24 sata, u bolnicama ukupno xxx osoba". Koronavirus.hr (in Croatian). 17 April 2021.
- "Covid19CubaData". Covid19CubaData (in Spanish). 16 April 2021.
- "CORONAVIRUS EN CUBA". Ministerio de Salud Pública [Ministry of Public Health] (in Spanish). 17 April 2021.
- Η εξάπλωση της COVID-19 στην Κύπρο. Πανεπιστήμιο Κύπρου [University of Cyprus] (in Greek). 16 April 2021.
- "Přehled situace v ČR: COVID-19". Ministerstvo zdravotnictví České republiky [The Ministry of Health of the Czech Republic] (in Czech). 16 April 2021.
- "Tal og overvågning over coronavirus/COVID-19 – Sundhedsstyrelsen". Sundhedsstyrelsen [The National Board of Health] (in Danish). 16 April 2021.
- "Statens Serum Institut COVID-19 – Danmark". Statens Serum Institut [The National Board of Health] (in Danish). 16 April 2021.
- "POINT DE PRESSE SUR LA SITUATION COVID19 PAR LE SECRÉTAIRE GÉNÉRAL DE LA SANTÉ DR MEEKE MOHAMED MOUSSA". Official Facebook account of the Ministere de la Santé de Djibouti [Djibouti Ministry of Health] (in French). 17 April 2021.
- "Commonwealth of Dominica Coronavirus [COVID-19] Report". Facebook account of the Ministry of Health, Wellness and New Health Investment. 2 April 2021.
- "Boletin Especial 375 COVID 19". Dirección General de Epidemiología [General Directorate of Epidemiology] (in Spanish). 16 April 2021.
- "Situation Épidémiologique en RDC". Stop Coronavirus COVID-19 RDC (in French). 28 February 2021.
- "Situación Nacional Por COVID-19 Infografía N°400" (PDF). Ministerio de Salud Pública [Ministry of Public Health] (in Spanish). 17 April 2021.
- "facebook.com/EgyMohpSpokes". Facebook page for the Egyptian Ministry of Health and Population (MOHP) spokesperson (in Arabic). 9 March 2021.
- "Situación nacional COVID-19". Gobierno de El Salvador [Government of El Salvador] (in Spanish). 15 April 2021.
- "Estadísticas COVID-19". Ministerio de Sanidad y Bienestar Social [Ministry of Health and Social Welfare] (in Spanish). Equatorial Guinea. 13 April 2021.
- "Koroonakaart". Koroonakaart. 17 April 2021.
- "COVID-19 Eswatini Dashboard". 13 April 2021.
- የኢትዮጵያ የተቀናጀ የኮቪድ-19 መቆጣጠሪያ ስርዓት. covid19.et (in Amharic). 5 March 2021.
- "Corona í Føroyum". Føroya Landsstýri [The Government of the Faroe Islands]. 16 April 2021.
- "COVID-19 Update" (PDF). Ministry of Health & Medical Services. Fiji. 17 April 2021.
- "Confirmed coronavirus cases (COVID-19) in Finland". Terveyden ja hyvinvoinnin laitos (ArcGIS) [National Institute for Health and Welfare (ArcGIS)]. 15 April 2021.
- "info coronavirus covid-19-carte et donnes covid 19 en france". Gouvernement.fr (in French). 17 April 2021.
- "SITUATION ÉPIDÉMIOLOGIQUE AU GABON". Info Covid19 Gabon (in French). 5 March 2021.
- "The Gambia COVID-19 Outbreak Situational Report" (PDF). Ministry of Health. 15 February 2021.
- COVID-19 სტატისტიკური მონაცემები. დაავადებათა კონტროლისა და საზოგადოებრივი ჯანმრთელობის ეროვნული ცენტრი [National Center for Disease Control and Public Health] (in Georgian). 17 April 2021.
- "Robert Koch-Institut: COVID-19-Dashboard". Robert Koch-Institut [Robert Koch Institute]. 14 April 2021.
- "Tabellen zu Testzahlen, Testkapazitäten und Probenrückstau pro Woche" (XLSX). Robert Koch-Institut [Robert Koch Institute]. 14 April 2021.
- "SITUATION UPDATE, COVID-19 OUTBREAK IN GHANA". Ghana Health Service. 30 March 2021.
- Ημερήσια έκθεση επιδημιολογικής επιτήρησης λοίμωξης από το νέο κορωνοϊό (COVID-19) (PDF). Εθνικός Οργανισμός Δημόσιας Υγείας [National Public Health Organization] (in Greek). 16 April 2021.
- "Coronavirus i Grønland". NAALAKKERSUISUT [GOVERNMENT OF GREENLEND] (in Danish). 16 April 2021.
- "COVID-19 Update | GRENADA DASHBOARD". Ministry of Health Grenada (Facebook). 25 March 2021.
- "Situación de COVID-19 en Guatemala". Ministerio de Salud Pública y Asistencia Social [Ministry of Public Health and Social Assistance] (in Spanish). 16 April 2021.
- "REPUBLIQUE DE GUINEE COVID-19 Décompte des cas". Official Twitter account of the Agence Nationale de Sécurité Sanitaire [National Agency for Health Security] (in French). 4 April 2021.
- "Situação Epidemiológica Da Covid-19 Na Guiné-Bissau". Official Facebook page of the Alto Comissariado para o Covid-19 [High Commissioner for Covid-19] (in Portuguese). 2 April 2021.
- "Guyana COVID-19 Dashboard". Ministry of Health. 17 April 2021.
- "Surveillance de la COVID-19, Haiti, 2020-2021" (PDF). Ministère de la Santé Publique et de la Population [Ministry of Public Health and Population] (in French). 26 March 2021.
- "Estadística Nacional de Coronavirus COVID-19". Biblio3eca Virtual en Salud de Honduras [Virtual Health Library of Honduras] (in Spanish). 17 April 2021.
- "Tájékoztató oldal a koronavírusról". Tájékoztató oldal a koronavírusról [Coronavirus Information Page] (in Hungarian). Cabinet Office of the Prime Minister. 17 April 2021.
- "COVID-19 in Iceland – Statistics". Covid.is. 16 April 2021.
- "SARS-CoV-2 (COVID-19) Testing: Status Update". Indian Council of Medical Research. Retrieved 17 April 2021.
- "Ministry of Health and Family Welfare". Ministry of Health and Family Welfare. Retrieved 17 April 2021.
- "Peta Sebaran". COVID-19 Handling and National Economic Recovery Committee. Retrieved 17 April 2021.
- "Peta Sebaran". COVID-19 Handling and National Economic Recovery Committee. 17 April 2021.
- "Health Ministry's Updates on COVID-19". Government of the Islamic Republic of Iran. 16 April 2021.
- "الموقف الوبائي اليومي لجائحة كورونا في العراق ليوم السبت الموافق ٥ كانون الاول ٢٠٢٠". وزارة الصحة العراقية (Facebook) [Iraqi Ministry of Health (Facebook)] (in Arabic). 17 April 2021.
- "Ireland's COVID-19 Data Hub". gov.ie. 16 April 2021.
- קורונה – לוח בקרה. נגיף הקורונה [Coronavirus] (in Hebrew). Ministry of Health. 16 April 2021.
- "17 Aprile 2021 – Aggiornamento casi Covid-19" (PDF). Dipartimento della Protezione Civile (GitHub) [Civil Protection Department (GitHub)] (in Italian). 17 April 2021.
- "Point de la situation de la COVID-19 au 3/03/2021". Official Facebook channel of Le Ministère de la Santé et de l’Hygiène Publique [Ministry of Health and Public Hygiene, Ivory Coast] (in French). 3 March 2021.
- "COVID-19 Clinical Management Summary". Ministry of Health & Wellness. 16 April 2021.
- 新型コロナウイルス感染症の現在の状況と厚生労働省の対応について（令和3年3月1日版）. 厚生労働省 [The Ministry of Health, Labour and Welfare] (in Japanese). 1 March 2021.
- "corona.moh.gov.jo/en". Jordan Ministry of Health. 16 April 2021.
- Данные по COVID-19 в Казахстане. Национальный центр общественного здравоохранения Министерства здравоохранения Республики Казахстан [National Center of Public Health of the Ministry of Healthcare of the Republic of Kazakhstan] (in Russian). 17 April 2021.
- "twitter.com/MOH_Kenya". Official Twitter Account of the Ministry of Health Kenya. 5 March 2021.
- "facebook.com/IKSHPK". Official Facebook account of the Instituti Kombëtar i Shëndetësisë Publike të Kosovës [National Institute of Public Health of Kosova] (in Albanian). 17 April 2021.
- "twitter.com/KUWAIT_MOH". Kuwait Minstry of Health (Twitter). 17 April 2021.
- За сутки проведено 3436 ПЦР-исследований на коронавирус. Insta official (in Kyrgyz). 10 February 2021.
- "ຄະນະສະເພາະກິດ COVID-19". COVID-19 Task Force (in Lao). 1 March 2021.
- "Covid-19 infekcijas izplatība Latvijā". Slimību profilakses un kontroles centrs (ArcGIS) [Center for Disease Prevention and Control (ArcGIS)] (in Latvian). 17 April 2021.
- آخر اﻹحصاءات. فيروس كورونا: COVID-19 [Coronavirus: COVID-19] (in Arabic). Ministry of Information. 17 April 2021.
- "COVID-19 Statistics". Official Twitter account of the National COVID-19 Secretariat (NACOSEC). 3 April 2021.
- "#LiBCOVID19 Case Update". Official Facebook account of the National Public Health Institute of Liberia-NPHIL. 4 March 2021.
- اليومي للوضع الوبائي المحلي لفيروس كورونا المستجد ليوم الأحد 28 فبراير 2021. Official Facebook account of the National Centre for Disease Control (NCDC) - Libya (in Arabic). 16 April 2021.
- "Koronavirusas (COVID-19)". Lietuvos Respublikos sveikatos apsaugos ministerija [Ministry of Health of the Republic of Lithuania] (in Lithuanian). 16 April 2021.
- "KORONA STOP". KORONA STOP. 5 March 2021.
- "CORONAVIRUS – RAPPORT JOURNALIER" (PDF). La plate-forme de données luxembourgeoise [The luxembourgish data platform] (in French). Government of Luxembourg. 16 April 2021.
- "COVID-19: Fivoaran'ny antontan'isa teto Madagasikara ny 13 Febroary ka hatramin'ny 19 Febroary 2021". Facebook account of the Ministère de la Santé Publique Madagascar [Ministry of Public Health Madagascar] (in French and Malagasy). 22 February 2021.
- "COVID-19 SITUATION UPDATE AS OF 3RD MARCH 2021". Facebook page of the Ministry Of Health - Malawi. 4 April 2021.
- "Situasi Terkini". Kementerian Kesihatan Malaysia [Ministry of Health Malaysia] (in Malay). 16 April 2021.
- "COVID-19 Case Updates". Health Protection Agency (Twitter). 16 April 2021.
- "COVID-19 LOCAL UPDATES". Ministry of Health. 29 January 2021.
- "COMMUNIQUE N°364 DU MINISTERE DE LA SANTE ET DU DÉVELOPPEMENT SOCIAL SUR LE SUIVI DES ACTIONS DE PREVENTION ET DE RIPOSTE FACE A LA MALADIE A CORONAVIRUS". Ministère de la Santé et du Développement Social du Mali [Ministry of Health and Social Development of Mali] (in French). 1 March 2021.
- "COVID-19 Malta". Times of Malta (ArcGIS). 17 April 2021.
- "المعطيات العامة للحالة الوبائية". Official Facebook page of the Ministère de la santé /وزارة الصحة [Ministry of Health] (in Arabic). Mauritania. 17 April 2021.
- "Covid-19 : Communiqués". Republic of Mauritius. 23 October 2020.
- "Covid-19 México". Gobierno de México [Government of Mexico] (in Spanish). 3 April 2021.
- "xxx cazuri de COVID-19, înregistrate în ultimele 24 ore". Ministerul Sănătății Muncii și Protecției Sociale [Ministry of Health, Labour and Social Protection] (in Romanian). Moldova. 17 April 2021.
- Нөхцөл байдлын мэдээ COVID-19. Эрүүл Мэндийн Яам [Ministry of Health] (in Mongolian). 13 April 2021.
- "Uživo: COVID-19". Institut za javno zdravlje Crne Gore [Institute of Public Health of Montenegro] (in Montenegrin). 4 August 2020.
- مرض فيروس كورونا المستجد: الرصد الصحي بالمغرب. البوابة الرسمية لفيروس كورونا بالمغرب [The official portal of coronavirus in Morocco] (in Arabic). 17 April 2021.
- "Boletim diário COVID-19 Nº379". Ministério da Saúde [Ministry of Health] (in Portuguese). 31 March 2021.
- "Coronavirus Disease 2019 (COVID-19) Surveillance Dashboard (Myanmar)". Ministry of Health and Sports (in Burmese). 2 April 2021.
- "COVID-19 update". Official Facebook account of the Ministry of Health and Social Services-Namibia. 16 April 2021.
- "COVID-19 Dashboard". Ministry of Health and Population (Nepal). Retrieved 1 March 2021.
- "Epidemiologische situatie van COVID-19 in Nederland" (PDF). Rijksinstituut voor Volksgezondheid en Milieu [National Institute for Public Health and the Environment] (in Dutch). 13 April 2021.
- "Info coronavirus Covid-19". Gouvernement de la Nouvelle-Calédonie [Government of New Caledonia] (in French). 17 April 2021.
- "COVID-19: Testing data". Ministry of Health. 14 April 2021.
- "COVID-19: Current cases". Ministry of Health. 16 April 2021.
- "#Covid19Niger Bilan du 22/02/2021". Facebook account of the Ministère de la Santé Publique [Ministry of Public Health] (in French). 22 February 2021.
- "Coronavirus COVID-19 Microsite". Nigeria Centre for Disease Control. 28 February 2021.
- КНДР ввела максимальный уровень карантина. KBS WORLD Radio (in Russian). 2 December 2020.
- РЕГИСТРИРАНИ 237 НОВИ СЛУЧАИ НА КОВИД 19 – ВКУПНО ДИЈАГНОСТИЦИРАНИ 84024, ОЗДРАВЕНИ 460 ПАЦИЕНТИ – ПОЧИНАТИ 8 ЛИЦA. Министерство за здравство [Ministry of Health] (in Macedonian). 27 January 2021.
- Во последните 24 часа. Министерство за здравство [Ministry of Health] (in Macedonian). 17 April 2021.
- "COVID-19 Genel Durum". Kuzey Kıbrıs Türk Cumhuriyeti Sağlık Bakanlığı [Turkish Republic of Northern Cyprus Ministry of Health] (in Turkish). 17 March 2021.
- "Dags- og ukerapporter om koronavirussykdom (covid-19)". Folkehelseinstituttet [Norwegian Institute of Public Health] (in Norwegian). 16 April 2021.
- "Oman conducts over 500,000 COVID-19 tests since the start of pandemic". The Arabian Stories. 28 October 2020.
- "Pakistan Cases Details". COVID-19 Health Advisory Platform. Ministry of National Health Services Regulations and Coordination. 5 March 2021.
- فايروس كورونا (COVID-19) في فلسطين. فايروس كورونا (COVID-19) في فلسطين [Coronavirus (COVID-19) in Palestine] (in Arabic). 16 April 2021.
- "Compartimos la actualización de datos sobre #COVID19 en nuestro país. Parte 1". Cuenta Oficial de Twitter del Ministerio de Salud de Panama [Official Twitter Account of the Ministry of Health Panama] (in Spanish). 17 April 2021.
- "Official COVID-19 Info Website". Papua New Guinea Joint Agency Task Force, National Control Centre for COVID-19. 20 February 2021.
- "Reportes – COVID19". Ministerio de Salud Pública y Bienestar Social [Ministry of Public Health and Social Welfare] (in Spanish). 14 April 2021.
- "Sala Situacional". Covid-19 en el Perú [Covid-19 in Peru] (in Spanish). 18 April 2021.
- "COVID-19 Tracker". Department of Health (Philippines). 16 April 2021.
- "COVID-19 Tracker". Department of Health (Philippines). 11 April 2021.
- "diagnostyka pod kątem koronawirusa". Official Twitter account of the Ministerstwo Zdrowia [Ministry of Health] (in Polish). 17 April 2021.
- "Ponto de Situação Atual em Portugal". COVID-19 (in Portuguese). Ministry of Health. 15 April 2021.
- "COVID19 Home". Ministry of Public Health. 16 April 2021.
- "Buletin informativ". Ministerul Sănătăţii [Ministry of Health] (in Romanian). 29 January 2021.
- Информационный бюллетень о ситуации и принимаемых мерах по недопущению распространения заболеваний, вызванных новым коронавирусом. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека (Роспотребнадзор) [Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)] (in Russian). 17 April 2021.
- О подтвержденных случаях новой коронавирусной инфекции COVID-2019 в России. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека (Роспотребнадзор) [Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)] (in Russian). 17 April 2021.
- "Amakuru Mashya | Update". Twitter account of the Ministry of Health-Rwanda. 17 April 2021.
- "COVID-19 Updates". Government of St. Kitts and Nevis. 15 April 2021.
- "Saint Lucia's COVID-19 Dashboard". Ministry of Health and Wellness. Retrieved 16 April 2021.
- "COVID-19 Report". Ministry of Health, Wellness and the Environment (St. Vincent and the Grenadines). 14 April 2021.
- "Aggiornamento Dati Epidemia COVID-19 a San Marino". Istituto per la Sicurezza Sociale [Institute for Social Security] (in Italian). 16 April 2021.
- "COVID 19 Dashboard: Saudi Arabia". Ministry of Health. 17 April 2021.
- "Riposte à l'épidémie du nouveau coronavirus COVID-19, Sénégal" (PDF). Ministère de la Santé et l'Action sociale [Ministry of Health and Social Action] (in French). 5 April 2021.
- "Coronavirus COVID-19". Ministry of Health of the Republic of Serbia. 17 April 2021.
- "Updates on COVID-19 (Coronavirus Disease 2019) Local Situation". Ministry of Health. 14 April 2021.
- "COVID-19 Situation Report". Ministry of Health. 2 March 2021.
- "Covid-19 in graphs". korona.gov.sk. Office of the Deputy Prime Minister of the Slovak Republic for Investments and Informatization. 17 April 2021.
- "Dnevno spremljanje okužb s SARS-CoV-2 (COVID-19)". Nacionalni inštitut za javno zdravje [National Institute of Public Health] (in Slovenian). 16 April 2021.
- "COVID-19 South African coronavirus news and information". South African Government. 17 April 2021.
- "COVID-19 statistics in South Africa". South Africa Health Twitter Account. 17 April 2021.
- 코로나바이러스감염증-19(COVID-19). 코로나바이러스감염증-19(COVID-19) [Coronavirus infection-19 (COVID-19)] (in Korean). Ministry of Health and Welfare. 1 March 2021.
- "UPDATE ON COVID-19 RESPONSE". Ministry of Health - South Sudan. 11 March 2021.
- "La pandemia del coronavirus, en datos, mapas y gráficos". RTVE ( Radio y Televisión Española) [RTVE ( Spanish Radio and Television)] (in Spanish). 15 April 2021.
- "Resumen de la situación - Pruebas de laboratorio". Ministerio de Sanidad, Consumo y Bienestar Social [Ministry of Health, Consumption and Social Welfare] (in Spanish). 12 April 2021.
- "COVID-19 Situation Report". Health Promotion Bureau, Sri Lanka. 31 March 2021.
- "COVID-19 : Live Situational Analysis Dashboard of Sri Lanka". Health Promotion Bureau, Sri Lanka. 31 March 2021.
- "Veckorapport om covid-19, vecka 13" (PDF). folkhalsomyndigheten.se (in Swedish). Public Health Agency of Sweden. 16 April 2021. p. 18.
- "Folkhalsomyndigheten Antal fall av Covid-19". folkhalsomyndigheten.se (in Swedish). Public Health Agency of Sweden. 1 February 2021.
- "COVID-19 Switzerland". Federal Office of Public Health FOPH. 16 April 2021.
- "Taiwan Centers for Disease Control". Taiwan Centers for Disease Control. 3 March 2021.
- รายงานสถานการณ์โรคติดเชื้อไวรัสโคโรนา 2019 ฉบับที่ 426 วันที่ 4 มีนาคม 2564 (PDF). Department of Disease Control (in Thai). 4 March 2021.
- "Coronavirus Au Togo". Government of Togo (in French). 4 April 2021.
- "COVID-19 Update Trinidad and Tobago". Ministry of Health. 10 April 2021.
- الأرقام الرئيسيّة المسجّلة بتاريخ 03 فيفري 2021 #كوفيد_19. Official Facebook account of the Ministére de la Santé وزارة الصحة [Ministry of Health, Tunisia] (in Arabic and French). 16 April 2021.
- "TÜRKİYE COVID-19 HASTA TABLOSU". Türkiye Cumhuriyeti Sağlık Bakanlığı [Republic of Turkey Ministry of Health] (in Turkish). 17 April 2021.
- "COVID-19 Daily Updates". Facebook page of the Ministry of Health - Uganda. 12 February 2021.
- "COVID-19 pandemic in Ukraine". COVID-19 pandemic in Ukraine. Cabinet of Ministers of Ukraine. 16 April 2021.
- "COVID-19 Information Center – Ministry of Health and Prevention – UAE". Ministry of Health & Prevention. 16 April 2021.
- "Coronavirus (COVID-19) in the UK". GOV.UK. 16 April 2021.
- "COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University". coronavirus.jhu.edu. 17 April 2021.
- "Covid Tracking US Daily". covidtracking.com. 9 March 2021.
- "Visualizador de casos coronavirus COVID-19 en Uruguay". Sistema Nacional de Emergencias [National Emergency System] (in Spanish). 16 April 2021.
- Число случаев COVID-19 превысило 13,8 тысячи. Gazeta.uz Газета.uz (in Russian). 14 July 2020.
- "Día 353 de la lucha contra la COVID-19". COVID-19 Patria (in Spanish). 30 March 2021.
- "COVID-19 in Viet Nam Situation Report 32". WHO. 6 April 2021. Retrieved 6 April 2021.
- "Daily #COVID19 update". Official Twitter account of the Zambia National Public Health Institute. 17 April 2021.
- "COVID-19 update". Official Twitter account of the Ministry of Health and Child Care (Zimbabwe). 5 March 2021.
- This article incorporates public domain material from the Centers for Disease Control and Prevention document: "Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19". Retrieved 5 May 2020.
- Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. (January 2020). "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR". Euro Surveill. 25 (3). doi:10.2807/1560-7917.ES.2020.25.3.2000045. PMC 6988269. PMID 31992387.
- Guglielmi G (July 2020). "The explosion of new coronavirus tests that could help to end the pandemic". Nature. 583 (7817): 506–9. Bibcode:2020Natur.583..506G. doi:10.1038/d41586-020-02140-8. PMID 32681157.
- Kevadiya, Bhavesh D.; Machhi, Jatin; Herskovitz, Jonathan; Oleynikov, Maxim D.; Blomberg, Wilson R.; Bajwa, Neha; Soni, Dhruvkumar; Das, Srijanee; Hasan, Mahmudul; Patel, Milankumar; Senan, Ahmed M. (15 February 2021). "Diagnostics for SARS-CoV-2 infections". Nature Materials: 1–13. doi:10.1038/s41563-020-00906-z. ISSN 1476-4660. PMID 33589798. S2CID 231930978.
|Wikimedia Commons has media related to COVID-19 testing.|
- "Coronavirus (COVID-19) Testing". Our World in Data. 13 July 2020. – International testing statistics updated twice a week.
- "COVID-19 diagnostic tech tableau". BioCentury. Retrieved 22 June 2020.
- COVID-19 Testing (at least) – now Free for all? (CDC; US Congress; CSPAN video/6:00; 12 March 2020)
- "EUA Authorized Serology Test Performance". U.S. Food and Drug Administration (FDA).
- "Global Progress on COVID-19 Serology-Based Testing". Johns Hopkins Center for Health Security.
- "Testing FAQ". Johns Hopkins Coronavirus Resource Center.